Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Sep. 30, 2020 | Dec. 11, 2020 | Mar. 31, 2020 | |
Document And Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Sep. 30, 2020 | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | BIOANALYTICAL SYSTEMS INC | ||
Entity Current Reporting Status | Yes | ||
Entity Central Index Key | 0000720154 | ||
Current Fiscal Year End Date | --09-30 | ||
Entity Filer Category | Non-accelerated Filer | ||
ICFR Auditor Attestation Flag | false | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Public Float | $ 24,989,000 | ||
Trading Symbol | BASI | ||
Entity Common Stock, Shares Outstanding | 11,058,366 | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Shell Company | false | ||
Entity Interactive Data Current | Yes | ||
Title of 12(b) Security | Common Shares | ||
Security Exchange Name | NASDAQ |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 1,406 | $ 606 |
Accounts receivable | ||
Trade, net of allowance of $561 at September 30, 2020 and $1,759 at September 30, 2019 | 8,681 | 7,178 |
Unbilled revenues and other | 2,142 | 2,342 |
Inventories, net | 700 | 1,095 |
Prepaid expenses | 2,371 | 1,200 |
Total current assets | 15,300 | 12,421 |
Property and equipment, net | 28,729 | 22,828 |
Operating lease right-of use-assets, net | 4,001 | 0 |
Finance lease right-to use assets, net | 4,778 | 0 |
Goodwill | 4,368 | 3,617 |
Other intangible assets, net | 4,261 | 2,883 |
Lease rent receivable | 75 | 130 |
Deferred tax asset | 0 | 31 |
Other assets | 81 | 70 |
Total assets | 61,593 | 41,980 |
Current liabilities: | ||
Accounts payable | 3,196 | 4,941 |
Restructuring liability | 168 | 349 |
Accrued expenses | 2,688 | 2,656 |
Customer advances | 11,392 | 6,726 |
Revolving line of credit | 0 | 1,063 |
Capex line of credit | 2,613 | 655 |
Current portion on long-term operating leases | 866 | 0 |
Current portion of long-term finance leases | 4,728 | 0 |
Current portion of long-term debt | 5,991 | 1,109 |
Total current liabilities | 31,642 | 17,499 |
Long-term operating leases, net | 3,344 | 0 |
Long-term finance leases, net | 44 | 0 |
Long-term debt, less current portion, net | 18,826 | 13,771 |
Deferred tax liability | 141 | 0 |
Total liabilities | 53,997 | 31,270 |
Shareholders' equity: | ||
Preferred shares, authorized 1,000,000 shares, no par value: 25 Series A shares at $1,000 stated value issued and outstanding at September 30, 2020 and 35 at September 30, 2019 | 25 | 35 |
Common shares, no par value: Authorized 19,000,000 shares; 10,977,675 issued and outstanding at September 30, 2020 and 10,510,694 at September 30, 2019 | 2,706 | 2,589 |
Additional paid-in capital | 26,775 | 25,183 |
Accumulated deficit | (21,910) | (17,097) |
Total shareholders' equity | 7,596 | 10,710 |
Total liabilities and shareholders' equity | $ 61,593 | $ 41,980 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
Allowance for Doubtful Accounts Receivable, Current | $ 561 | $ 1,759 |
Common Stock, No Par Value | $ 0 | $ 0 |
Common Stock, Shares Authorized | 19,000,000 | 19,000,000 |
Common Stock, Shares, Issued | 10,977,675 | 10,510,694 |
Common Stock, Shares, Outstanding | 10,977,675 | 10,510,694 |
Series A Preferred Stock [Member] | ||
Preferred Stock, Shares Authorized | 1,000,000 | 1,000,000 |
Preferred Stock, No Par Value | $ 0 | $ 0 |
Preferred Stock, Shares Issued | 25 | 35 |
Preferred Stock, Shares Outstanding | 25 | 35 |
Preferred Stock, Par or Stated Value Per Share | $ 1,000 | $ 1,000 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Total revenue | $ 60,469 | $ 43,616 |
Total cost of revenue | 42,232 | 29,581 |
Gross profit | 18,237 | 14,035 |
Operating expenses: | ||
Selling | 3,373 | 2,914 |
Research and development | 950 | 627 |
General and administrative | 16,977 | 10,647 |
Total operating expenses | 21,300 | 14,188 |
Operating loss | (3,063) | (153) |
Interest expense | (1,490) | (642) |
Other income | 15 | 9 |
Net loss before income taxes | (4,538) | (786) |
Income tax expense | 147 | 4 |
Net loss | $ (4,685) | $ (790) |
Basic net loss per share: (In dollars per share) | $ (0.43) | $ (0.08) |
Diluted net loss per share: (In dollar per share) | $ (0.43) | $ (0.08) |
Weighted common shares outstanding: | ||
Basic (in shares) | 10,851 | 10,383 |
Diluted (in shares) | 10,851 | 10,383 |
Service [Member] | ||
Total revenue | $ 57,177 | $ 39,048 |
Total cost of revenue | 40,006 | 27,435 |
Product [Member] | ||
Total revenue | 3,292 | 4,568 |
Total cost of revenue | $ 2,226 | $ 2,146 |
CONSOLIDATED STATEMENTS OF SHAR
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands | Preferred Shares [Member] | Common Shares [Member] | Additional paid-in capital [Member] | Accumulated deficit [Member]Adoption of accounting standard | Accumulated deficit [Member] | Adoption of accounting standard | Total |
Balance at Sep. 30, 2018 | $ 35 | $ 2,523 | $ 24,557 | $ (16,231) | $ 10,884 | ||
Balance (in shares) at Sep. 30, 2018 | 35 | 10,245,277 | |||||
Net loss | (790) | (790) | |||||
Stock issued in acquisition | $ 50 | 344 | 394 | ||||
Stock issued in acquisition (In shares) | 200,000 | ||||||
Stock based compensation expense | $ 14 | 278 | 292 | ||||
Stock based compensation (in shares) | 54,615 | ||||||
Stock option exercises | $ 0 | $ 2 | 4 | 6 | |||
Stock option exercises (in shares) | 10,802 | ||||||
Balance at Sep. 30, 2019 | $ 35 | $ 2,589 | 25,183 | $ (76) | (17,097) | $ (76) | 10,710 |
Balance (in shares) at Sep. 30, 2019 | 35 | 10,510,694 | |||||
Net loss | (4,685) | (4,685) | |||||
Stock issued in acquisition | $ 60 | 1,073 | 1,133 | ||||
Stock issued in acquisition (In shares) | 240,000 | ||||||
Stock based compensation expense | $ 29 | 511 | 540 | ||||
Stock based compensation (in shares) | 108,233 | ||||||
Stock option exercises | $ 27 | (1) | 26 | ||||
Stock option exercises (in shares) | 0 | 113,748 | |||||
Preferred stock conversion | $ (10) | $ 1 | 9 | 0 | |||
Preferred stock conversion (in shares) | (10) | 5,000 | |||||
Balance at Sep. 30, 2020 | $ 25 | $ 2,706 | $ 26,775 | $ (128) | $ (21,910) | $ (128) | $ 7,596 |
Balance (in shares) at Sep. 30, 2020 | 25 | 10,977,675 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Operating activities: | ||
Net loss | $ (4,685) | $ (790) |
Adjustments to reconcile net loss to net cash provided by operating activities, net of acquisition: | ||
Depreciation and amortization | 3,929 | 2,717 |
Amortization finance lease | 145 | 0 |
Change on operating lease | 211 | 0 |
stock compensation expense | 540 | 278 |
Provision for doubtful accounts | 180 | 0 |
Loss on disposal of property and equipment | 10 | 1 |
Unrealized foreign currency (gain) loss | 12 | (159) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (620) | (3,265) |
Inventories | 395 | 87 |
Income tax accruals | 184 | (3) |
Prepaid expenses and other assets | (1,149) | (113) |
Accounts payable | (2,047) | 1,019 |
Accrued expenses | (130) | 849 |
Customer advances | 4,315 | 1,156 |
Net cash provided by operating activities | 1,290 | 1,777 |
Investing activities: | ||
Capital expenditures | (6,200) | (6,878) |
Cash paid in acquisition | (3,931) | (1,271) |
Net cash used in investing activities | (10,131) | (8,149) |
Financing activities: | ||
Payments on finance lease liability | (319) | 0 |
Payments of long-term borrowings | (1,847) | (909) |
Payments of debt issuance costs | (127) | (94) |
Payments on revolving line of credit | (25,325) | (28,662) |
Borrowings on revolving line of credit | 24,263 | 29,725 |
Borrowings on construction loan | 1,287 | 4,301 |
Borrowings on capex line of credit | 2,906 | 655 |
Payments on capital lease obligations | 0 | (88) |
Borrowings on long-term loan | 8,777 | 1,271 |
Proceeds from exercise of stock options | 26 | 6 |
Net cash provided by financing activities | 9,641 | 6,205 |
Net increase (decrease) in cash and cash equivalents | 800 | (167) |
Cash and cash equivalents at beginning of year | 606 | 773 |
Cash and cash equivalents at end of year | 1,406 | 606 |
Supplemental disclosure of cash flow information: | ||
Cash paid for interest | 1,039 | 566 |
Cash paid for acquisitions: | ||
Assets acquired | 6,442 | 3,384 |
Liabilities assumed | (1,378) | (1,719) |
Common shares issued | (1,133) | (394) |
Cash paid | $ 3,931 | $ 1,271 |
DESCRIPTION OF THE BUSINESS AND
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION | 12 Months Ended |
Sep. 30, 2020 | |
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION | |
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION | 1. DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Bioanalytical Systems, Inc. and its subsidiaries, including as operating under the trade name “Inotiv” (“We,” “Our,” “Us,” the “Company,” “BASi” and “Inotiv”) engage in contract laboratory research services and other services related to pharmaceutical development, chemical and medical device development, biomedical research and government-sponsored research. The Company also manufactures scientific instruments for life sciences research, which we sell with related software for use by pharmaceutical companies, universities, government research centers and medical research institutions. Our customers are located throughout the world. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Sep. 30, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated. (b) Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. (c) Revenue Recognition In accordance with Accounting Standards Codification (“ASC”) 606, the Company disaggregates its revenue from clients into three revenue streams, service revenue, product revenue and royalties. At contract inception the Company assesses the services promised in the contract with the clients to identify performance obligations in the arrangements. Service revenue The Company enters into contracts with clients to provide drug discovery and development services with payments based on mainly fixed-fee arrangements. The Company also offers archive storage services to our clients. The Company’s fixed fee arrangements may involve nonclinical research services (toxicology, pathology, pharmacology), bioanalytical, and pharmaceutical method development and validation, nonclinical research services and the analysis of bioanalytical and pharmaceutical samples. For bioanalytical and pharmaceutical method validation services and nonclinical research services, revenue is recognized over time using the input method based on the ratio of direct costs incurred to total estimated direct costs. For contracts that involve in-life study conduct, method development or the analysis of bioanalytical and pharmaceutical samples, revenue is recognized over time when samples are analyzed or when services are performed. The Company generally bills for services on a milestone basis. These contracts represent a single performance obligation and due to the Company’s right to payment for work performed, revenue is recognized over time. Research services contract fees received upon acceptance are deferred until earned and classified within customer advances on the consolidated balance sheets. Unbilled revenues represent revenues earned under contracts in advance of billings. Archive services provide climate controlled archiving for client’s data and samples. The archive revenue is recognized over time, generally when the service is provided. These arrangements include one performance obligation. Amounts related to future archiving or prepaid archiving contracts for clients where archiving fees are billed in advance are accounted for as deferred revenue and recognized ratably over the period the applicable archive service is performed. Product revenue The Company’s products can be sold to multiple clients and have alternative use. Both the transaction sales price and shipping terms are agreed upon in the client order. For these products, all revenue is recognized at a point in time, generally when title of the product and control is transferred to the client based upon shipping terms. These arrangements typically include only one performance obligation. Certain products have maintenance agreements available for clients to purchase. These are typically billed in advance and are accounted for as deferred revenue, are recognized ratably over the applicable maintenance period and are included in customer advances on the consolidated balance sheet. Royalty revenue The Company has an agreement with Teva Pharmaceuticals (formerly Biocraft Laboratories, Inc,) which manufactures and markets pharmaceutical products. The Company receives royalties in accordance with sales of certain pharmaceuticals that Teva manufactures and sells. The royalties are received on a quarterly basis and the revenue is recognized over the quarter. Royalty revenue is included in service revenue on the consolidated statement of operations. Total revenue recognized was $641 and $349 in the years ended September 30, 2020 and 2019, respectively. The following table presents changes in the Company’s contract liabilities for the year ended September 30, 2020. Fiscal year ended September 30, 2020 2019 Opening balance $ 6,726 $ 4,925 Additions 106,956 34,650 Deductions (102,290) (32,849) Ending balance $ 11,392 $ 6,726 (d) Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to certain limits. At times, cash in the bank deposit may exceed federally insured limits. (e) Accounts Receivable The Company performs periodic credit evaluations of our clients’ financial conditions and generally do not require collateral on trade accounts receivable. We account for trade receivables based on the amounts billed to clients. Past due receivables are determined based on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined by management based on our historical losses, specific client circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables when all attempts to collect have failed. Our allowance for doubtful accounts was $561 and $1,759 at September 30, 2020 and 2019, respectively. A summary of activity in our allowance for doubtful accounts is as follows: Fiscal year ended September 30, 2020 2019 Opening balance $ 1,759 $ 1,948 Charged to expense 180 — Uncollectible invoices written off (1,378) (49) Amounts collected — (140) Ending balance $ 561 $ 1,759 (f) Inventories Inventories are stated at the lower of cost or net realizable value using the first-in, first-out (FIFO) cost method of accounting. The Company evaluates inventory on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand. A summary of activity in our inventory obsolescence is as follows for the years ended September 30, 2020 and 2019: Fiscal year ended September 30, 2020 2019 Opening balance $ 198 $ 188 Provision for slow moving and obsolescence 84 97 Write-off of obsolete and slow moving inventory (105) (87) Closing balance $ 177 $ 198 (g) Property and Equipment The Company records property and equipment acquired as part of business combinations at fair value while other property and equipment is recorded at cost, including interest capitalized during the period of construction of major facilities. Depreciation, including amortization on capital leases, is computed using the straight-line method over the estimated useful lives of the assets, which we estimate to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10 years. Expenditures for maintenance and repairs are expensed as incurred unless the life of the asset is extended beyond one year, which would qualify for asset treatment. Depreciation expense was $3,126 in fiscal 2020 and $2,223 in fiscal 2019. Property and equipment, net, as of September 30, 2020 and 2019 consisted of the following: 2020 2019 Land and improvements $ 1,755 $ 1,048 Buildings and improvements 29,882 22,418 Machinery and equipment 30,731 25,323 Office furniture and fixtures 950 905 Construction in progress 718 6,010 64,036 55,704 Less: accumulated depreciation (35,307) (32,876) Net property and equipment $ 28,729 $ 22,828 (h) Long-Lived Assets including Goodwill Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company carries goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized . At September 30, 2020 and 2019, respectively, the remaining recorded goodwill was $4,368 and $3,617. The increase of $751 is attributable to the Pre-clinical Research Services, Inc., (PCRS) acquisition as described in Note 11. The Company reviews goodwill for impairment on an annual basis in accordance with ASC 350, Intangibles- Goodwill and Other. In evaluating the goodwill, we must make assumptions regarding the discounted future cash flows of the reporting unit with goodwill. If the discounted cash flows are less than the carrying value, we then determine if an impairment loss is recognized by evaluating the fair value of the goodwill. The Company utilizes fair value techniques accepted by ASC 820, which include the income, market and cost approach. If the fair value of the goodwill is less than the carrying amount, we recognize an impairment loss. Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain risks. The Company had one reporting unit with goodwill at September 30, 2020 which was our Services business, which is included in our Services operating segment, based on the discrete financial information available which is reviewed by management. An annual goodwill impairment test was performed for the Services reporting unit at September 30, 2020 and there was no indication of impairment. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing after fiscal year-end. At September 30, 2020 the intangible assets subject to amortization totaled $4,261 as compared to $2,883 at September 30, 2019. The increase in intangible assets relate to the PCRS acquisition described in Note 11. The changes in the balances of the intangible assets for the years ended September 30, 2020 and 2019 are as follows: Client Non-Compete Trademarks Relationships Agreements Backlog Patents Totals Balance as of October 1, 2018 $ 1,150 $ 1,918 $ 178 $ 72 $ 16 $ 3,334 Amortization (78) (248) (47) (72) (6) (451) Balance as of September 30, 2019 $ 1,072 $ 1,670 $ 131 $ — $ 10 $ 2,883 Acquisition of PCRS 460 1,280 220 121 — 2,081 Amortization (103) (380) (93) (121) (6) (703) Balance as of September 30, 2020 $ 1,429 $ 2,570 $ 258 $ — $ 4 $ 4,261 Future amortization expense for intangible assets at September 30, 2020 for the next five years and a total, thereafter, are as follows: 2021 2022 2023 2024 2025 Thereafter Totals Trademarks 109 109 109 109 109 884 1,429 Client Relationships 408 408 408 408 408 530 2,570 Non-Compete Agreements 102 91 55 10 - - 258 Patents 4 - - - - - 4 $ 623 $ 608 $ 572 $ 527 $ 517 $ 1,414 $ 4,261 (i) Stock-Based Compensation The Company has a stock option plan and an equity incentive plan for officers, outside directors and employees, which are described more fully in Note 9. The Company recognizes the cost resulting from all share-based payment transactions in our financial statements using a fair-value based method. Compensation cost for all share-based awards are measured based on estimated fair values and compensation is recognized over the vesting period for awards. The Company uses the binomial option valuation model to determine the grant date fair value. The determination of fair value is affected by our common share price as well as assumptions regarding subjective and complex variables such as expected employee exercise behavior and our expected stock price volatility over the term of the award. Generally, our assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. We estimated the following key assumptions for the binomial valuation calculation: · Risk-free interest rate . The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant for the expected term of the option. · Expected volatility . The Company uses our historical share price volatility on our common shares for our expected volatility assumption. · Expected term . The expected term represents the weighted-average period the stock options are expected to remain outstanding. The expected term is determined based on historical exercise behavior, post-vesting termination patterns, options outstanding and future expected exercise behavior. · Expected dividends . The Company assumes that we will pay no dividends. Employee stock-based compensation expense recognized in fiscal 2020 and 2019 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment will be recognized at that time. (j) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position. The Company records interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months. (k) Fair Value of Financial Instruments The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: · Level 1 – Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. · Level 2 – Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. · Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The carrying value of the credit facility approximates fair value as it was amended during fiscal year 2020 and subsequent to the amendment, there have been no factors that would indicate a change in the carrying value As of September 30, 2020 and 2019, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis. (l) Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values, allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation. Our actual results could differ from those estimates. (m) Research and Development In fiscal 2020 and 2019, the Company incurred $950 and $627, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business. The Company expenses research and development costs as incurred. (n) Debt issuance costs The Company capitalizes costs associated with the issuance of debt and amortizes them as additional interest expense over the lives of the debt on a straight-line basis, which approximates the effective interest method. The Company believes the difference between the straight-line basis and the effective interest method is not material to the consolidated financial statements. Debt issuance costs of $235 and $207, as of September 30, 2020 and 2019, respectively, were netted with long-term debt less current portion on the consolidated balance sheets. Upon prepayment of the related debt, the Company accelerates the recognition of an appropriate amount of the costs as refinancing or extinguishment of debt. (o) New Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued updated guidance on leases which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. On October 1, 2019, the Company adopted ASC 842 Leases (ASU 2016-02) and all the related amendments to its lease contracts using the modified retrospective method. The effective date was used as the Company’s date of initial application with no restatement of prior periods. As such prior periods continue to be reported under the accounting standards in effect for those periods. The Company recorded upon adoption a financing right-of-use asset and lease liability on the consolidated balance sheet of $4,628 and $4,650, respectively, and an operating right-of-use asset and lease liability of $4,581 and $4,687, respectively. The lease liability reflects the present value of the Company’s estimated future minimum lease payments over the term of the lease, which includes options that are reasonably certain to be exercised, discounted utilizing a collateralized incremental borrowing rate. The impact of the new lease standard does not affect the Company’s operating cash flows. See Note 6 for additional information. In June 2016, the FASB issued ASU 2016-13 “Financial Instruments (Topic 326) Measurement of Credit Losses on Financial Instrument” “CECL”). ASU 2016-13 requires an allowance for expected credit losses on financial assets to be recognized as early as day one of the instrument. This ASU departs from the incurred loss model which means the probability threshold is removed. It considers more forward-looking information and requires the entity to estimate its credit losses as far as it can reasonably estimate. This update became effective for the Company on October 1, 2020. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. (p) Building Lease The Lease Agreement with Cook Biotech, Inc. (“lessee”) for a portion of the Company’s headquarters facility is recorded as an operating lease with the escalating rents being recognized on a straight-line basis once the lessee took full possession of the space on May 1, 2015 through the end of the lease on December 31, 2024. The straight-line rents of $53 per month are recorded as a reduction to general and administrative expenses on the consolidated statements of operations and other accounts receivable on the consolidated balance sheets. The cash rent received is recorded in lease rent receivable on the consolidated balance sheets. The variance between the straight-line rents recognized and the actual cash rents received will net to zero by the end of the agreement on December 31, 2024. |
SALE OF PREFERRED SHARES AND WA
SALE OF PREFERRED SHARES AND WARRANTS | 12 Months Ended |
Sep. 30, 2020 | |
SALE OF PREFERRED SHARES AND WARRANTS | |
SALE OF PREFERRED SHARES AND WARRANTS | 3. SALE OF PREFERRED SHARES AND WARRANTS (not in thousands) On May 11, 2011, the Company completed a registered public offering of 5,506 units at a price of $1,000 per unit. Each unit consisted of one 6% Series A convertible preferred share which is convertible into 500 common shares. The Series A preferred shares were valued using the common shares available upon conversion of all preferred shares of 2,753,000 and the closing market price of our stock on May 11, 2011 of $1.86. As of September 30, 2020, 5,481 preferred shares have been converted into 3,144,108 common shares and 217,366 common shares have been issued for quarterly preferred dividends for remaining outstanding, unconverted preferred shares. At September 30, 2020, 25 preferred shares remained outstanding. All dividends have been paid according to the agreement. |
LOSS PER SHARE
LOSS PER SHARE | 12 Months Ended |
Sep. 30, 2020 | |
LOSS PER SHARE | |
LOSS PER SHARE | 4. LOSS PER SHARE The Company computes basic income (loss) per share using the weighted average number of common shares outstanding. The Company has two categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options, respectively. Shares issuable upon exercise of 712 stock options and 12 common shares issuable upon conversion of preferred shares were not considered in computing diluted income (loss) per share for the year ended September 30, 2020, because they were anti-dilutive. Shares issuable upon exercise of 776 stock options and 17 common shares issuable upon conversion of preferred shares were not considered in computing diluted income (loss) per share for the year ended September 30, 2019, because they were anti-dilutive. Computation of basic net loss per share is shown in the following table: Years Ended September 30, 2020 2019 Basic net (loss) per share: Net loss applicable to common shareholders $ (4,685) $ (790) Weighted average common shares outstanding 10,851 10,383 Basic net loss per share $ (0.43) $ (0.08) For purposes of the diluted net income (loss) per share calculation, stock options and Series A preferred shares are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. These common stock equivalents were excluded from the determination of diluted net loss per share in fiscal 2020 due to their anti-dilutive effect on earnings. |
INVENTORIES
INVENTORIES | 12 Months Ended |
Sep. 30, 2020 | |
INVENTORIES | |
INVENTORIES | 5. INVENTORIES Inventories consisted of the following: As of September 30, 2020 2019 Raw materials $ 577 $ 858 Work in progress 70 89 Finished goods 230 346 $ 877 $ 1,293 Obsolescence reserve (177) (198) $ 700 $ 1,095 |
LEASES
LEASES | 12 Months Ended |
Sep. 30, 2020 | |
LEASES | |
LEASES | 6. LEASES The Company has various operating and finance leases for facilities and equipment. Facilities leases provide office, laboratory, warehouse, or land, the Company uses to conduct its operations. Facilities leases range in duration from two to ten years, with either renewal options for additional terms as the initial lease term expires, or purchase options. Facilities leases are considered as either operating or financing leases. Equipment leases provide for office equipment, laboratory equipment or services the Company uses to conduct its operations. Equipment leases range in duration from 30 to 60 months, with either subsequent annual renewals, additional terms as the initial lease term expires, or purchase options. Effective October 1, 2019, the Company adopted ASC 842, Leases, using a modified retrospective transition approach which applies the standard to leases existing at the effective date with no restatement of prior periods. The Company’s operating leases have been included in operating lease right-of-use assets, current portion of operating lease liabilities and long-term portion of operating lease liabilities in the consolidated balance sheet. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the leases. The Company elected to apply the following practical expedients and accounting policy elections permitted by the standard at transition: · The Company has elected that it will not reassess contracts that have expired or existed at the date of adoption for 1) leases under the new definition of a lease, 2) lease classification, 3) whether previously capitalized initial direct costs would qualify for capitalization under the standard. · The Company elected not to separate lease and non-lease components. · The Company elected not to assess whether any land easements are, or contain, leases. · The Company elected to record leases with an initial term of 12 months or less directly in the consolidated statement of operations. Right-of-use lease assets and lease liabilities that are reported in the Company’s consolidated balance sheets are as follows: As of September 30, 2020 Operating right-of-use assets, net $ 4,001 Current portion of operating lease liabilities 866 Long-term operating lease liabilities 3,344 Total operating lease liabilities $ 4,210 Finance right-of-use assets, net $ 4,778 Current portion of finance lease liabilities 4,728 Long-term finance lease liabilities 44 Total finance lease liabilities $ 4,772 During the twelve months ended September 30, 2020, the Company had operating lease amortizations of $906, and finance lease amortization of $145. Finance lease interest recorded in the twelve months ended September 30, 2020 was $283. One of the operating leases contains a variable lease component based on revenue for one component of the Company. The total variable payments for this lease for fiscal year 2020 was $126. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The components of lease expense related to the Company’s lease for the twelve months ended September 30, 2020 were: Twelve months ended September 30, 2020 Operating lease costs: Fixed operating lease costs $ 906 Short-term lease costs 41 Variable lease costs 1 Sublease income (636) Finance lease costs: Amortization of right-of-use asset expense 145 Interest on finance lease liability 283 Total lease cost $ 740 The Company serves as lessor to a lessee in one facility through the end of calendar year 2024. The gross rental income and underlying lease expense are presented gross in the Company’s consolidated balance sheet. The Company received rental income of $636 for twelve months ended September 30, 2020. Supplemental cash flow information related to leases was as follows: Twelve months Ended September 30, 2020 Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 948 Operating cash flows from finance leases 283 Finance cash flows from finance leases 145 Non-cash lease activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 448 The weighted average remaining lease term and discount rate for the Company’s operating and finance leases as of September 30, 2020 were: As of September 30, 2020 Weighted-average remaining lease term (in years) Operating lease Finance lease 0.88 Weighted-average discount rate (in percentages) Operating lease 5.23 % Finance lease 5.87 % Lease duration was determined utilizing renewal options that the Company is reasonably certain to execute. As of September 30, 2020, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases 2021 $ 896 $ 4,929 2022 938 19 2023 979 13 2024 1,349 13 2025 452 5 Thereafter 194 — Total minimum future lease payments 4,808 4,979 Less interest (598) (207) Total lease liability 4,210 4,772 |
DEBT
DEBT | 12 Months Ended |
Sep. 30, 2020 | |
DEBT | |
DEBT | 7. DEBT Credit Facility On December 1, 2019, in connection with the PCRS Acquisition, the Company entered into an Amended and Restated Credit Agreement (the "Credit Agreement") with First Internet Bank of Indiana (“FIB"). The Credit Agreement was amended on March 27, 2020 to modify the definition of Adjusted EBITDA for purposes of covenant calculations and to modify the terms of the Initial Capex Line. The Credit Agreement includes five term loans (the “Initial Term Loan," "Second Term Loan,” "Third Term Loan," "Fourth Term Loan," and "Fifth Term Loan," respectively), a revolving line of credit (the “Revolving Facility”), a construction draw loan (the “Construction Draw Loan”), an equipment draw loan (the “Equipment Draw Loan”), and two capital expenditure instruments (the "Initial Capex Line" and the "Second Capex Line," respectively). The Initial Term Loan for $4,500 bears interest at a fixed rate of 3.99%, with monthly principal and interest payments of approximately $33. The Initial Term Loan matures June 23, 2022. The balance on the Initial Term Loan at September 30, 2020 was $3,748. We used the proceeds from the Initial Term Loan to satisfy our indebtedness with Huntington Bank and terminated the related interest rate swap. The Second Term Loan for $5,500 was used to fund a portion of the cash consideration for the Seventh Wave acquisition. Amounts outstanding under the Second Term Loan bear interest at a fixed per annum rate of 5.06%, with monthly principal and interest payments equal to $78. The Second Term Loan matures July 2, 2023 and the balance on the Second Term Loan at September 30, 2020 was $4,004. The Third Term Loan for $1,271 was used to fund the cash consideration for the Smithers Avanza acquisition. Amounts outstanding under the Third Term Loan bear interest at a fixed per annum rate of 4.63%. The Third Term Loan required monthly interest only payments until December 1, 2019, from which time payments of principal and interest in monthly installments of $20 are required, with all accrued but unpaid interest, cost and expenses due and payable at the maturity date. The Third Term Loan matures November 1, 2025 and the balance on the Third Term Loan at September 30, 2020 was $1,115. The Fourth Term Loan in the principal amount of $1,500 has a maturity of June 1, 2025. Interest accrues on the Fourth Term Loan at a fixed per annum rate equal to 4%, with interest payments only commencing January 1, 2020 through June 1, 2020, with monthly payments of principal and interest thereafter through maturity. The balance on the Fourth Term Loan at September 30, 2020 was $1,425. The Fifth Term loan in the principal amount of $1,939 has a maturity of December 1, 2024. Interest accrues on the Fifth Term Loan at a fixed per annum rate equal to 4%, with payments of principal and interest due monthly through maturity. The balance on the Fifth Term Loan at September 30, 2020 was $1,891. We entered into the Fourth Term Loan and the Fifth Term Loan in connection with the PCRS Acquisition. The Revolving Facility provides a line of credit for up to $5,000, which the Company may borrow from time to time, subject to the terms of the Credit Agreement, including as may be limited by the amount of the Company’s outstanding eligible receivables. As of September 30, 2020, the Revolving Facility had a maturity of January 31, 2021. The Revolving Facility requires monthly accrued and unpaid interest payments only until maturity at a floating per annum rate equal to the greater of (a) 4%, or (b) the sum of the Prime Rate plus Zero Basis Points (0.0%), which rate shall change concurrently with the Prime Rate. The Company did not have an outstanding balance on the Revolving Facility as of September 30, 2020. On December 18, 2020, the parties amended the Revolving Note to extend its maturity through May 31, 2021. Refer to Item 9B. The Construction Draw Loan provides for borrowings up to a principal amount not to exceed $4,445 and the Equipment Draw Loan provides for borrowings up to a principal amount not to exceed $1,429. The Construction Draw Loan and Equipment Draw Loan each mature on March 28, 2025. As of September 30, 2020, there was a $4,230 balance on the Construction Draw Loan and a $1,266 balance on the Equipment Draw Loan. Subject to certain conditions precedent, the Construction Draw Loan and an Equipment Draw Loan each permitted the Company to obtain advances aggregating up to the maximum principal amount available for such loan through March 28, 2020. Amounts outstanding under these loans bear interest at a fixed per annum rate of 5.20%. The Construction Draw Loan and the Equipment Draw Loan each require monthly payments of accrued interest on amounts outstanding through March 28, 2020, and thereafter monthly payments of principal and interest on amounts then outstanding through maturity. We have utilized funds from the Construction Draw Loan and the Equipment Draw Loan in connection with the Evansville facility expansion. The Initial Capex Line previously provided for borrowings up to the principal amount of $1,100, which the Company could borrow from time to time, subject to the terms of the Credit Agreement. On March 27, 2020, the parties amended the Initial Capex Line to eliminate the revolving nature of the line in favor of a term loan in the principal amount of $948, equivalent to the amount of borrowings then outstanding on the Initial Capex Line. As amended, the Initial Capex Line matures on June 30, 2025, and as of September 30, 2020, had a balance of $920. Interest accrues on the principal balance of the Initial Capex Line at a fixed per annum rate equal to 4%. The Company is required to pay accrued but unpaid interest on the Initial Capex Line on a monthly basis until June 30, 2020. Commencing August 1, 2020, and on the first day of each monthly period thereafter until and including on the maturity date, the Initial Capex Line requires payments of principal and interest in monthly installments equal to $17. As of September 30, 2020, the Second Capex Line provided for borrowings up to the principal amount of $3,000, subject to the terms of the Credit Agreement, with a maturity of December 31, 2020 and interest payments only until maturity at a floating per annum rate equal to the greater of (a) 4%, or (b) the sum of the Prime Rate plus Fifty Basis Points (0.5%), which rate shall change concurrently with the Prime Rate. At September 30, 2020, the balance on the Second Capex Line was $2,613. On December 18, 2020, the parties amended the Second Capex Line to eliminate the revolving nature of the line in favor of a term loan in the principal amount of $3,000, equivalent to the amount of borrowings then outstanding on the Second Capex Line. Refer to Item 9B. The Company’s obligations under the Credit Agreement are guaranteed by BAS Evansville, Inc. (“BASEV”), Seventh Wave Laboratories, LLC, BASi Gaithersburg LLC, as well as Bronco Research Services LLC (“Bronco”), each a wholly owned subsidiary of the Company (collectively, the "Guarantors"). The Company’s obligations under the Credit Agreement and the Guarantor's obligations under their respective guaranties are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors, respectively, mortgages on the Company’s BASEV’s and Bronco’s facilities in West Lafayette, Indiana, Evansville, Indiana, and Fort Collins, Colorado, respectively, and pledges of the Company’s ownership interests in its subsidiaries. As of September 30, 2020, the Credit Agreement included financial covenants consisting of (i) a Fixed Charge Coverage Ratio (as defined in the Credit Agreement) of not less than 1.25 to 1.0, tested quarterly and measured on a trailing twelve (12) month basis and (ii) beginning March 31, 2020 a Cash Flow Leverage Ratio (as defined in the Credit Agreement), tested quarterly, as follows: not to exceed (a) as of March 31, 2020, 5.00 to 1.00, (b) as of June 30, 2020, 4.50 to 1.00, (c) as of September 30, 2020, 4.25 to 1.00 and (d) as of December 31, 2020 and each quarter thereafter, 4.00 to 1.00. An amendment to the Credit Agreement on March 27, 2020 modified the definition of Adjusted EBITDA, including for purposes of covenant calculations. As amended, the calculation of Adjusted EBITDA includes (i) the addition of a decreasing amount of proforma EBITDA from Pre-Clinical Research Services, Inc. (which the Company acquired in the first quarter of fiscal 2020) for each quarter of fiscal 2020 and (ii) the addition or subtraction of certain non-cash expenses or income recognized. Upon an event of default, which includes certain customary events such as, among other things, a failure to make required payments when due, a failure to comply with covenants, certain bankruptcy and insolvency events, and defaults under other material indebtedness, FIB may cease advancing funds, increase the interest rate on outstanding balances, accelerate amounts outstanding, terminate the agreement and foreclose on all collateral. The Company has also agreed to obtain a life insurance policy in an amount not less than $5,000 for its President and Chief Executive Officer and to provide FIB an assignment of such life insurance policy as collateral. The Company entered into Credit Agreement modifications on August 13, 2020 and December 18, 2020 with FIB. Based in part on the impact of COVID-19 on the Company’s operations and financial performance, FIB suspended testing of the Fixed Charge Coverage Ratio and the Cash Flow Leverage Ratio for the June 30, 2020 and September 30, 2020 compliance periods, respectively, and suspended testing of the Fixed Charge Coverage Ratio for the December 31, 2020 compliance period. The December 18, 2020 modification, also revised the Company’s covenant calculations on a go-forward basis, as described in Item 9B. Absent these suspensions and modifications, the Company would not have been in compliance with the covenants for the June 30, 2020 and September 30, 2020 measurement periods and expects that it would not have been in compliance with the covenants for the December 31, 2020 measurement period. Refer to Item 9B for additional details. The modification on August 13, 2020 updated the definition of Total Funded Debt under the Credit Agreement to exclude the funding of the Company’s $5,051 loan pursuant to the Paycheck Protection Program (PPP) under Division A, Title 1 of the CARES Act until the SBA has made a determination regarding forgiveness of the loan. Any PPP loan balance not forgiven will thereafter immediately be deemed funded debt for purposes of the Total Funded Debt definition. In addition to the indebtedness under our Credit Agreement, as part of the Smithers Avanza acquisition, we have an unsecured promissory note payable to the Smithers Avanza seller in the initial principal amount of $810 made by BASi Gaithersburg and guaranteed by the Company. The promissory note bears interest at 6.5% with monthly payments and maturity date of May 1, 2022. At September 30, 2020, the balance on the note payable to the Smithers Avanza seller was $650. As part of the PCRS acquisition, we also have an unsecured promissory note payable to the PCRS seller in the initial principal amount of $800. The promissory note bears interest at 4.5% with monthly payments and a maturity date of December 1, 2024. At September 30, 2020, the balance on the note payable to the PCRS seller was $752. On April 23, 2020, the Company was granted a loan (the “Loan”) from Huntington National Bank in the aggregate amount of $5,051, pursuant to the Paycheck Protection Program (PPP) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The principal and accrued interest under the Loan is to be repaid in eighteen installments of $283 beginning on November 16, 2020 and continuing monthly until the final payment is due on April 16, 2022. The Company has applied for the forgiveness of the loan in the amount of $4,851. Long-term debt is detailed in the table below. As of: September 30, 2020 September 30, 2019 Initial term loan $ 3,748 $ 3,990 Second term loan 4,004 4,715 Third term loan 1,115 1,271 Fourth term loan 1,425 — Fifth term loan 1,891 — Initial Capex line 920 — Subtotal term loans 13,103 9,976 Construction and equipment loans 5,496 4,301 Seller note – Smithers Avanza 650 810 Seller note – Pre-Clinical Research Services 752 — Paycheck protection program loan 5,051 — 25,052 15,087 Less: Current portion (5,991) (1,109) Less: Debt issue costs not amortized (235) (207) Total Long-term debt $ 18,826 $ 13,771 Cash interest payments of $1,039 and $566 were made in 2020 and 2019, respectively. The following table summarizes the combined aggregate amount of maturities over the next five fiscal years: 2021 2022 2023 2024 2025 Thereafter Total Long-term debt $ 5,991 $ 8,110 $ 4,075 $ 1,608 $ 5,227 $ 41 $ 25,052 |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Sep. 30, 2020 | |
INCOME TAXES | |
INCOME TAXES | 8. INCOME TAXES Significant components of our deferred tax assets and liabilities are as follows: As of September 30, 2020 2019 Deferred tax assets: Inventory $ 85 $ 102 Accrued compensation and vacation 137 162 Accrued expenses and other 172 379 Domestic net operating loss carryforwards 3,580 3,282 Basis difference for intangible assets 457 254 Stock compensation expense 96 2 AMT credit carryover — 31 Leases 108 — PPP loan expenses 1,276 — Total deferred tax assets 5,911 4,212 Deferred tax liabilities: Prepaid expenses (143) (121) Basis difference for fixed assets (211) (219) Goodwill (141) — Total deferred tax liabilities (495) (340) Total net deferred tax assets 5,416 3,872 Valuation allowance for net deferred tax assets (5,557) (3,841) Net deferred tax asset (liability) $ (141) $ 31 Significant components of the provision (benefit) for income taxes are as follows as of the year ended September 30: 2020 2019 Current: Federal $ (31) $ (31) State and local 6 4 Deferred: Federal 143 31 State and local 29 — Income tax expense $ 147 $ 4 The effective income tax rate on continuing operations varied from the statutory federal income tax rate as follows: 2020 2019 Federal statutory income tax rate 21.0 % 21.0 % Increases (decreases): State and local income taxes, net of Federal tax benefit, if applicable (0.1) % (0.4) % Other nondeductible expenses 1.3 % (11.5) % Goodwill (3.1) % — Valuation allowance changes (22.3) % (9.6) % Effective income tax rate (3.2) % (0.5) % The Company has indefinite-lived intangible assets related to goodwill. These intangible assets are not amortized for financial reporting purposes; however, they are tax deductible and therefore amortized over 15 years for tax purposes. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax deductibility of the assets. The resulting deferred tax liability, which will continue to increase over time, will have an indefinite life and could remain on the Company’s balance sheet permanently unless there is impairment of the related assets (for financial reporting purposes), or the business to which those assets relate are disposed of. The reversal of the deferred tax liability related to the indefinite-lived goodwill cannot be determined or considered a source of income for valuation allowance purposes. Therefore, the result is a valuation allowance in excess of net deferred tax assets and a net credit balance (“naked credit” deferred tax liability). Realization of deferred tax assets associated with the net operating loss carryforward and credit carryforward is dependent upon generating sufficient taxable income prior to their expiration. The valuation allowance in fiscal 2020 and 2019 was $5,557 and $3,841, respectively for our domestic operations. Payments made in fiscal 2020 and 2019 for income taxes amounted to $7 and $7, respectively. At September 30, 2020, the Company had domestic net operating loss carryforwards for federal tax purposes of $11,859, which expire from September 30, 2032 through 2036. State and local loss carryforwards total approximately $22,506. The majority expire from September 30, 2028 through 2038; however, approximately $465 may be carried forward indefinitely, as they relate to states conforming to the provisions of the Tax Cuts and Jobs Act which allowed for an indefinite carryforward period of losses generated after December 31, 2017. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon regulatory examination based on the technical merits of the position. The amount of the benefit for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position. There have been no additional gross uncertain tax positions during fiscal 2020 based on any federal or state tax position. The Company is no longer subject to U.S. Federal tax examinations for years before 2016 or state and local for years before 2015, with limited exceptions. For federal purposes, the tax attributes carried forward could be adjusted through the examination process and are subject to examination 3 years from the date of utilization. The Company has assessed the application of Internal Revenue Code Section 382 regarding certain limitations on the future usage of net operating losses. No limitation applies as of September 30, 2020 and we will continue to monitor activities in the future. On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security (CARES) Act, due to the coronavirus pandemic. Among other things, the legislation provides tax relief for businesses. The Company is still assessing the tax benefit, if any, that it could receive under this legislation. The Company received a PPP loan of $5,051 and applied for forgiveness of $4,851. Based on satisfaction of requirements under the CARES Act for forgiveness, the Company has recorded a deferred tax asset for nondeductible expense relating to the PPP funds of $1,276. |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 12 Months Ended |
Sep. 30, 2020 | |
STOCK-BASED COMPENSATION | |
STOCK-BASED COMPENSATION | 9. STOCK-BASED COMPENSATION Summary of Equity Plans and Activity In March 2008, the Company's shareholders approved the 2008 Stock Option Plan (the “Plan”) to replace the 1997 Outside Director Stock Option Plan and the 1997 Employee Stock Option Plan. The purpose of the Plan was to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees. The Compensation Committee administered the Plan and approved the particular officers, directors or employees eligible for grants. Under the Plan, employees were granted the option to purchase our common shares at fair market value on the day prior to the date of the grant. Generally, options granted vest and become exercisable in three equal installments commencing one year from date of grant and expire upon the earlier of the employee’s termination of employment with us, or ten years from the date of grant. In March 2018, the Company's shareholders approved the amendment and restatement of the Plan in the form of the Amended and Restated 2018 Equity Incentive Plan and in March 2020 the shareholders approved a further amendment to increase the number of shares issuable under the amended and restated plan by 700 and to make corresponding changes to the number of shares issuable as incentive options and as restricted stock or pursuant to restricted stock units (as amended, the "Equity Plan"). The Company currently grants equity awards from the Equity Plan. The purpose of the Equity Plan is to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees. The maximum number of new common shares that may be granted under the Equity Plan is 700 shares plus the remaining shares from the 2008 Stock Option Plan. At September 30, 2020, 814 shares remained available for grants under the Plan. In fiscal 2020, 152 options were granted to employees and independent directors. In fiscal 2019, 503 options were granted to employees and independent directors. The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30, 2020 and 2019 were as follows: 2020 2019 Risk-free interest rate 1.36 % 2.47 % Dividend yield 0.00 % 0.00 % Volatility of the expected market price of the Company’s common shares 76.56 % 72.14 % Expected life of the options (years) 5.95 5.95 A summary of our stock option activity for all options and related information for the year ended September 30, 2020, is as follows (in thousands except for share prices): Weighted- Weighted- Average Average Remaining Aggregate Options Exercise Contractual Intrinsic (shares) Price Life Value Outstanding - October 1, 2019 776 $ 1.61 7.98 $ 1,536 Exercised (154) $ 1.56 Granted 152 $ 4.56 Forfeited (62) $ 2.05 Outstanding - September 30, 2020 712 $ 2.21 7.59 $ 1,939 Exercisable at September 30, 2020 281 $ 1.64 6.38 $ 922 The aggregate intrinsic value is the product of the total options outstanding and the net positive difference of our common share price on September 30, 2020 and the options’ exercise price. The total intrinsic value of stock options exercised for fiscal years ended September 30, 2020 and 2019 were $562 and $19, respectively. The weighted average estimated fair value of stock options granted for the fiscal years ended September 30, 2020 and 2019 were $3.11 and $1.09 per stock option, respectively. As of September 30, 2020, our total unrecognized compensation cost related to non-vested stock options was $545 and is expected to be recognized over a weighted-average service period of 2.0 years. During the year ended September 30, 2020, the Company granted a total of 126 shares to officers, outside directors and employees. A summary of our restricted share activity for the year ended September 30, 2020 is as follows: Weighted- Average Grant Restricted Shares Date Fair Value Outstanding - September 30, 2019 20 $ 2.0 Granted 126 $ 4.2 Unvested shares forfeited (18) $ 4.0 Outstanding - September 30, 2020 128 $ 3.9 As of September 30, 2020, our total unrecognized compensation cost related to unvested restricted stock was $326 and is expected to be recognized over a weighted-average service period of 1.4 years. The total fair value of the restricted shares granted during the year ended September 30, 2020 was $528. Stock-based compensation expense for employee stock options and restricted stock for the years ended September 30, 2020 and 2019 was $540 and $278, respectively. |
RETIREMENT PLAN
RETIREMENT PLAN | 12 Months Ended |
Sep. 30, 2020 | |
RETIREMENT PLAN | |
RETIREMENT PLAN | 10. RETIREMENT PLAN The Company has a 401(k) Retirement Plan (the “Plan”) covering all employees with at least 90 days of service. Under the terms of the Plan, the Company matches 50% of the first 6% of the employee contribution. The Plan also includes provisions for various contributions which may be instituted at the discretion of the Board of Directors. The contribution made by the participant may not exceed the annual limits set by the IRS. Contribution expense was $538 and $374 in fiscal 2020 and 2019, respectively. The contribution expense increased primarily due to growth in overall headcount through organic growth and the PCRS acquisition in December 2019 as well as changing the company match from one year of service eligibility to 90 days eligibility. |
BUSINESS COMBINATIONS
BUSINESS COMBINATIONS | 12 Months Ended |
Sep. 30, 2020 | |
BUSINESS COMBINATIONS | |
BUSINESS COMBINATIONS | 11. BUSINESS COMBINATIONS The Company accounts for acquisitions in accordance with guidance found in ASC 805, Business Combinations. The guidance requires consideration given, including contingent consideration, assets acquired, and liabilities assumed to be valued at their fair market values at the acquisition date. The guidance further provides that: (1) in-process research and development will be recorded at fair value as an indefinite-lived intangible asset; (2) acquisition costs will generally be expensed as incurred, (3) restructuring costs associated with a business combination will generally be expensed subsequent to the acquisition date; and (4) changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date generally will affect income tax expense. ASC 805 requires that any excess of purchase price over fair value of assets acquired, including identifiable intangibles and liabilities assumed, be recognized as goodwill. Smithers Avanza Toxicology Services LLC acquisition Overview On May 1, 2019, the Company, through its wholly-owned subsidiary BASi Gaithersburg LLC (f/k/a Oriole Toxicology Services LLC) (the “ Smithers Avanza Purchaser”), acquired (the “Smithers Avanza Acquisition”) from Smithers Avanza Toxicology Services LLC (the “Smithers Avanza Seller”), a consulting-based contract research laboratory located in Gaithersburg, Maryland, substantially all of the assets used by the Smithers Avanza Seller in connection with the performance of in-vivo mammalian toxicology CRO services for pharmaceuticals (small molecules and biologics), vaccines, agro and industrial chemicals, under the terms and conditions of an Asset Purchase Agreement, dated May 1, 2019, among the Smithers Avanza Purchaser, the Company, the Smithers Avanza Seller and the member of the Smithers Avanza Seller (the “Smithers Avanza Purchase Agreement”). The total consideration for the Smithers Avanza Acquisition was $2,595, which consisted of $1,271 in cash, subject to certain adjustments and an indemnity escrow of $125,200 of the Company’s common shares valued at $394 using the closing price of the Company’s common shares on April 30, 2019 and an unsecured promissory note in the initial principal amount of $810 made by the Smithers Avanza Purchaser and guaranteed by the Company. The promissory note bears interest at 6.5%. The Company funded the cash portion of the purchase price for the Smithers Avanza Acquisition with cash on hand and the net proceeds from the refinancing of its credit arrangements with FIB. The Smithers Avanza Purchase Agreement contains customary representations, warranties, covenants (including non-competition requirements applicable to the selling parties for a 5-year period) and indemnification provisions. As contemplated by the Smithers Avanza Purchase Agreement, on May 1, 2019 the Smithers Avanza Purchaser assumed amended lease arrangements for certain premises in Gaithersburg, Maryland (the “Lease Arrangements”). Under the Lease Arrangements, the Smithers Avanza Purchaser agreed to lease the premises for a term of 5 years and 8 months, with two 5-year extensions at the Smithers Avanza Purchaser’s option. Annual minimum rental payments under the initial term of the Lease Arrangements range from $400 to $600, provided that the Lease Arrangements provide the Smithers Avanza Purchaser with the option to purchase the premises. The Lease Arrangements include customary rights upon a default by landlord or tenant. Accounting for the Transaction Results are included in the Company’s results from the acquisition date of May 1, 2019. The Company’s allocation of the $2,595 purchase price to Smithers Avanza’s tangible and identifiable intangible assets acquired and liabilities assumed, based on their estimated fair values as of May 1, 2019, is included in the table below. Goodwill, which is derived from the enhanced scientific expertise, expanded client base and our ability to provide broader service solutions through a comprehensive portfolio, is recorded based on the amount by which the purchase price exceeds the fair value of the net assets acquired and is deductible for tax purposes. The purchase price allocation as of September 30, 2020 was as follows: Allocation as of September 30, 2020 Assets acquired and liabilities assumed: Receivables $ 1,128 Property and equipment 1,564 Prepaid expenses 147 Goodwill 545 Accrued expenses (219) Customer advances (570) $ 2,595 The allocation of the purchase price is based on valuations performed to determine the fair value of such assets and liabilities as of the acquisition date. Goodwill from this transaction is allocated to the Company’s Services segment. Smithers Avanza recorded revenues of $10,748 and net loss of $596 for the twelve-month period ending September 30, 2020. PCRS acquisition Overview On November 8, 2019, the Company and Bronco Research Services LLC, a wholly owned subsidiary of the Company (the “PCRS Purchaser”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Pre-Clinical Research Services, Inc., a Colorado corporation (the “PCRS Seller”), and its shareholder. Pursuant to the Purchase Agreement, on December 1, 2019, the Company indirectly acquired (the “PCRS Acquisition”) substantially all of the assets of PCRS Seller used or useful by PCRS Seller in connection with PCRS Seller's provision of GLP and non-GLP preclinical testing for the pharmaceutical and medical device industries. The total consideration for the PCRS Acquisition was $5,857, which consisted of $1,500 in cash, subject to certain adjustments, 240 of the Company’s common shares valued at $1,133 using the closing price of the Company’s common shares on November 29, 2019 and an unsecured promissory note in the initial principal amount of $800 made by PCRS Purchaser. The promissory note bears interest at 4.5%. The Company also purchased certain real property located in Fort Collins, Colorado, comprising the main facility for the PCRS Seller’s business and additional property located next to the facility available for future expansion, for $2,500. The Company funded the cash portion of the purchase price for the PCRS Acquisition with cash on hand and the net proceeds from the refinancing of its credit arrangements with FIB, as described in Note 7. As contemplated by the Purchase Agreement, the Company also entered into a lease arrangement for an ancillary property used by PCRS Seller’s business, located in Livermore, Colorado. Accounting for the Transaction Results are included in the Company’s results from the acquisition date of December 1, 2019. The Company’s allocation of the $5,857 purchase price to PCRS’s tangible and identifiable intangible assets acquired and liabilities assumed, based on their estimated fair values as of December 1, 2019, is included in the table below. Goodwill, which is derived from the enhanced scientific expertise, expanded client base and our ability to provide broader service solutions through a comprehensive portfolio, is recorded based on the amount by which the purchase price exceeds the fair value of the net assets acquired and is deductible for tax purposes. The purchase price allocation as of September 30, 2020 was as follows: Allocation as of September 30, 2020 Assets acquired and liabilities assumed: Receivable $ 578 Property and equipment 2,836 Unbilled receivables 162 Prepaid expenses 27 Intangible assets 2,081 Goodwill 751 Accounts payable (109) Accrued expenses (118) Customer advances (351) $ 5,857 The allocation of the purchase price is based on valuations performed to determine the fair value of such assets and liabilities as of the acquisition date. Goodwill from this transaction is allocated to the Company’s Services segment. The Company incurred transaction costs of $248 for the twelve months ended September 30, 2020 related to the PCRS Acquisition. These costs were expensed as incurred and were primarily recorded as selling, general, and administrative expenses on the Company’s consolidated statements of operations. PCRS recorded revenues of $4,780 and net income of $176 for the twelve-month period ending September 30, 2020. Pro Forma Results The Company’s unaudited pro forma results of operations for the twelve months ended September 30, 2020 assuming the Smithers Avanza Acquisition and the PCRS Acquisition had occurred as of October 1, 2019 are presented for comparative purposes below. These amounts are based on available information of the results of operations of the Smithers Avanza Seller’s operations and the PCRS Seller’s operations prior to the acquisition date and are not necessarily indicative of what the results of operations would have been had the Smithers Avanza Acquisition and PCRS Acquisition been completed on October 1, 2019. The unaudited pro forma information is as follows: Twelve Months Ended September 30, 2019 Total revenues $ 51,661 Net loss (2,808) Pro forma basic net loss per share $ (0.26) Pro forma diluted net loss per share $ (0.26) |
SEGMENT INFORMATION
SEGMENT INFORMATION | 12 Months Ended |
Sep. 30, 2020 | |
SEGMENT INFORMATION | |
SEGMENT INFORMATION | 12. SEGMENT INFORMATION The Company operates in two principal segments - research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. The accounting policies of these segments are the same as those described in the summary of significant accounting policies. (a) Operating Segments Years Ended September 30, 2020 2019 Revenue: Services $ 57,177 $ 39,048 Products 3,292 4,568 $ 60,469 $ 43,616 Operating income (loss): Services $ 8,210 $ 5,579 Products (437) (95) Unallocated corporate (10,836) (5,636) $ (3,063) $ (153) Interest expense (1,490) (642) Other income 15 9 Income (loss) before income taxes $ (4,538) $ (786) Years Ended September 30, Years Ended September 30, 2020 2019 2020 2019 Identifiable assets: Depreciation and amortization: Services $ 54,480 $ 35,695 Services $ 3,127 $ 2,017 Products 1,535 1,780 Products 23 19 Unallocated corporate 5,578 4,505 Unallocated corporate 779 681 $ 61,593 $ 41,980 $ 3,929 $ 2,717 Goodwill, net: Capital expenditures: Services $ 4,368 $ 3,617 Services $ 4,781 $ 5,936 Products — — Products 9 29 Unallocated corporate — — Unallocated corporate 1,410 913 $ 4,368 $ 3,617 $ 6,200 $ 6,878 (b) Geographic Information Years Ended September 30, 2020 2019 Sales to External Customers: United States $ 56,253 $ 39,634 Other North America 148 218 Pacific Rim 2,826 2,407 Europe 1,207 1,217 Other 35 140 $ 60,469 $ 43,616 Long-lived Assets: United States $ 28,729 $ 22,828 $ 28,729 $ 22,828 (c) Major Clients Sales are predominately to customers located principally in the United States. The Company extends trade credit to its customers on terms that are generally practiced in the industry. As of and for the years ended September 30, 2020 and 2019, no customers accounted for more than 10 percent of sales or accounts receivable. |
ACCRUED EXPENSES
ACCRUED EXPENSES | 12 Months Ended |
Sep. 30, 2020 | |
ACCRUED EXPENSES | |
ACCRUED EXPENSES | 13. ACCRUED EXPENSES As part of a fiscal 2012 restructuring, the Company accrued for lease payments at the cease use date for our United Kingdom facility and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. Based on these matters, we had a $1,117 reserve for lease related costs and for legal and professional fees and other costs to remove improvements previously made to the facility. During fiscal 2020, the Company released portions of the reserve for lease related liabilities that were no longer owed due to the statute of limitations. At September 30, 2020 and September 30, 2019, respectively, we had $168 and $349 reserved for the remaining liability. The reserve is classified as a current liability on the condensed consolidated balance sheets. |
RELATED-PARTY TRANSACTIONS
RELATED-PARTY TRANSACTIONS | 12 Months Ended |
Sep. 30, 2020 | |
RELATED-PARTY TRANSACTIONS | |
RELATED-PARTY TRANSACTIONS | 14. RELATED-PARTY TRANSACTIONS In April 2017, the Company renewed a consulting agreement with a shareholder, incurring $76 and $75 in fees and reimbursed travel costs in fiscal 2020 and fiscal 2019, respectively. Additionally, the Company has a consulting agreement with LS Associates by which we paid consulting fees of $64 and $156 in fiscal 2020 and fiscal 2019, respectively. LS Associates is owned in part by our CEO, Robert W. Leasure Jr. The Company received consulting services form LS Associates prior to Mr. Leasure being elected as CEO and continues to use services of the consulting firm on an as needed basis. The Company leases space from SWL Properties, LLC. SWL Properties is owned by three employees of the company, two of which are officers. The lease term is seven years, with the possibility of extension for two successive terms of seven years each. The lease also includes an option to purchase the building during the first five years of the lease at fair market value. The lease is reflected as a financing lease on the balance sheet. Lease expense incurred was $390 in each of the fiscal years 2020 and 2019. The Company has an unsecured promissory note in the initial principal amount of $800 made by PCRS Purchaser, who is an affiliate of the Company. See description of promissory note in Note 7. In addition, the affiliate leases space to the Company. The initial term of the lease is five years with the possibility of extension for two successive terms of five years each. The lease is reflected as an operating lease on the balance sheet. Lease expense incurred was $85 in fiscal 2020. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Sep. 30, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Principles of Consolidation | (a) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated. |
Reclassification of Prior Year Presentation | (b) Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. |
Revenue Recognition | (c) Revenue Recognition In accordance with Accounting Standards Codification (“ASC”) 606, the Company disaggregates its revenue from clients into three revenue streams, service revenue, product revenue and royalties. At contract inception the Company assesses the services promised in the contract with the clients to identify performance obligations in the arrangements. Service revenue The Company enters into contracts with clients to provide drug discovery and development services with payments based on mainly fixed-fee arrangements. The Company also offers archive storage services to our clients. The Company’s fixed fee arrangements may involve nonclinical research services (toxicology, pathology, pharmacology), bioanalytical, and pharmaceutical method development and validation, nonclinical research services and the analysis of bioanalytical and pharmaceutical samples. For bioanalytical and pharmaceutical method validation services and nonclinical research services, revenue is recognized over time using the input method based on the ratio of direct costs incurred to total estimated direct costs. For contracts that involve in-life study conduct, method development or the analysis of bioanalytical and pharmaceutical samples, revenue is recognized over time when samples are analyzed or when services are performed. The Company generally bills for services on a milestone basis. These contracts represent a single performance obligation and due to the Company’s right to payment for work performed, revenue is recognized over time. Research services contract fees received upon acceptance are deferred until earned and classified within customer advances on the consolidated balance sheets. Unbilled revenues represent revenues earned under contracts in advance of billings. Archive services provide climate controlled archiving for client’s data and samples. The archive revenue is recognized over time, generally when the service is provided. These arrangements include one performance obligation. Amounts related to future archiving or prepaid archiving contracts for clients where archiving fees are billed in advance are accounted for as deferred revenue and recognized ratably over the period the applicable archive service is performed. Product revenue The Company’s products can be sold to multiple clients and have alternative use. Both the transaction sales price and shipping terms are agreed upon in the client order. For these products, all revenue is recognized at a point in time, generally when title of the product and control is transferred to the client based upon shipping terms. These arrangements typically include only one performance obligation. Certain products have maintenance agreements available for clients to purchase. These are typically billed in advance and are accounted for as deferred revenue, are recognized ratably over the applicable maintenance period and are included in customer advances on the consolidated balance sheet. Royalty revenue The Company has an agreement with Teva Pharmaceuticals (formerly Biocraft Laboratories, Inc,) which manufactures and markets pharmaceutical products. The Company receives royalties in accordance with sales of certain pharmaceuticals that Teva manufactures and sells. The royalties are received on a quarterly basis and the revenue is recognized over the quarter. Royalty revenue is included in service revenue on the consolidated statement of operations. Total revenue recognized was $641 and $349 in the years ended September 30, 2020 and 2019, respectively. The following table presents changes in the Company’s contract liabilities for the year ended September 30, 2020. Fiscal year ended September 30, 2020 2019 Opening balance $ 6,726 $ 4,925 Additions 106,956 34,650 Deductions (102,290) (32,849) Ending balance $ 11,392 $ 6,726 |
Cash Equivalents | (d) Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to certain limits. At times, cash in the bank deposit may exceed federally insured limits. |
Accounts Receivable | (e) Accounts Receivable The Company performs periodic credit evaluations of our clients’ financial conditions and generally do not require collateral on trade accounts receivable. We account for trade receivables based on the amounts billed to clients. Past due receivables are determined based on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined by management based on our historical losses, specific client circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables when all attempts to collect have failed. Our allowance for doubtful accounts was $561 and $1,759 at September 30, 2020 and 2019, respectively. A summary of activity in our allowance for doubtful accounts is as follows: Fiscal year ended September 30, 2020 2019 Opening balance $ 1,759 $ 1,948 Charged to expense 180 — Uncollectible invoices written off (1,378) (49) Amounts collected — (140) Ending balance $ 561 $ 1,759 |
Inventories | (f) Inventories Inventories are stated at the lower of cost or net realizable value using the first-in, first-out (FIFO) cost method of accounting. The Company evaluates inventory on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand. A summary of activity in our inventory obsolescence is as follows for the years ended September 30, 2020 and 2019: Fiscal year ended September 30, 2020 2019 Opening balance $ 198 $ 188 Provision for slow moving and obsolescence 84 97 Write-off of obsolete and slow moving inventory (105) (87) Closing balance $ 177 $ 198 |
Property and Equipment | (g) Property and Equipment The Company records property and equipment acquired as part of business combinations at fair value while other property and equipment is recorded at cost, including interest capitalized during the period of construction of major facilities. Depreciation, including amortization on capital leases, is computed using the straight-line method over the estimated useful lives of the assets, which we estimate to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10 years. Expenditures for maintenance and repairs are expensed as incurred unless the life of the asset is extended beyond one year, which would qualify for asset treatment. Depreciation expense was $3,126 in fiscal 2020 and $2,223 in fiscal 2019. Property and equipment, net, as of September 30, 2020 and 2019 consisted of the following: 2020 2019 Land and improvements $ 1,755 $ 1,048 Buildings and improvements 29,882 22,418 Machinery and equipment 30,731 25,323 Office furniture and fixtures 950 905 Construction in progress 718 6,010 64,036 55,704 Less: accumulated depreciation (35,307) (32,876) Net property and equipment $ 28,729 $ 22,828 |
Long-Lived Assets including Goodwill | (h) Long-Lived Assets including Goodwill Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company carries goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized . At September 30, 2020 and 2019, respectively, the remaining recorded goodwill was $4,368 and $3,617. The increase of $751 is attributable to the Pre-clinical Research Services, Inc., (PCRS) acquisition as described in Note 11. The Company reviews goodwill for impairment on an annual basis in accordance with ASC 350, Intangibles- Goodwill and Other. In evaluating the goodwill, we must make assumptions regarding the discounted future cash flows of the reporting unit with goodwill. If the discounted cash flows are less than the carrying value, we then determine if an impairment loss is recognized by evaluating the fair value of the goodwill. The Company utilizes fair value techniques accepted by ASC 820, which include the income, market and cost approach. If the fair value of the goodwill is less than the carrying amount, we recognize an impairment loss. Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain risks. The Company had one reporting unit with goodwill at September 30, 2020 which was our Services business, which is included in our Services operating segment, based on the discrete financial information available which is reviewed by management. An annual goodwill impairment test was performed for the Services reporting unit at September 30, 2020 and there was no indication of impairment. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing after fiscal year-end. At September 30, 2020 the intangible assets subject to amortization totaled $4,261 as compared to $2,883 at September 30, 2019. The increase in intangible assets relate to the PCRS acquisition described in Note 11. The changes in the balances of the intangible assets for the years ended September 30, 2020 and 2019 are as follows: Client Non-Compete Trademarks Relationships Agreements Backlog Patents Totals Balance as of October 1, 2018 $ 1,150 $ 1,918 $ 178 $ 72 $ 16 $ 3,334 Amortization (78) (248) (47) (72) (6) (451) Balance as of September 30, 2019 $ 1,072 $ 1,670 $ 131 $ — $ 10 $ 2,883 Acquisition of PCRS 460 1,280 220 121 — 2,081 Amortization (103) (380) (93) (121) (6) (703) Balance as of September 30, 2020 $ 1,429 $ 2,570 $ 258 $ — $ 4 $ 4,261 Future amortization expense for intangible assets at September 30, 2020 for the next five years and a total, thereafter, are as follows: 2021 2022 2023 2024 2025 Thereafter Totals Trademarks 109 109 109 109 109 884 1,429 Client Relationships 408 408 408 408 408 530 2,570 Non-Compete Agreements 102 91 55 10 - - 258 Patents 4 - - - - - 4 $ 623 $ 608 $ 572 $ 527 $ 517 $ 1,414 $ 4,261 |
Stock-Based Compensation | (i) Stock-Based Compensation The Company has a stock option plan and an equity incentive plan for officers, outside directors and employees, which are described more fully in Note 9. The Company recognizes the cost resulting from all share-based payment transactions in our financial statements using a fair-value based method. Compensation cost for all share-based awards are measured based on estimated fair values and compensation is recognized over the vesting period for awards. The Company uses the binomial option valuation model to determine the grant date fair value. The determination of fair value is affected by our common share price as well as assumptions regarding subjective and complex variables such as expected employee exercise behavior and our expected stock price volatility over the term of the award. Generally, our assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. We estimated the following key assumptions for the binomial valuation calculation: · Risk-free interest rate . The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant for the expected term of the option. · Expected volatility . The Company uses our historical share price volatility on our common shares for our expected volatility assumption. · Expected term . The expected term represents the weighted-average period the stock options are expected to remain outstanding. The expected term is determined based on historical exercise behavior, post-vesting termination patterns, options outstanding and future expected exercise behavior. · Expected dividends . The Company assumes that we will pay no dividends. Employee stock-based compensation expense recognized in fiscal 2020 and 2019 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment will be recognized at that time. |
Income Taxes | (j) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position. The Company records interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months. |
Fair Value of Financial Instruments | (k) Fair Value of Financial Instruments The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: · Level 1 – Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. · Level 2 – Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. · Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The carrying value of the credit facility approximates fair value as it was amended during fiscal year 2020 and subsequent to the amendment, there have been no factors that would indicate a change in the carrying value As of September 30, 2020 and 2019, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis. |
Use of Estimates | (l) Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values, allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation. Our actual results could differ from those estimates. |
Research and Development | (m) Research and Development In fiscal 2020 and 2019, the Company incurred $950 and $627, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business. The Company expenses research and development costs as incurred. |
Debt issuance costs | (n) Debt issuance costs The Company capitalizes costs associated with the issuance of debt and amortizes them as additional interest expense over the lives of the debt on a straight-line basis, which approximates the effective interest method. The Company believes the difference between the straight-line basis and the effective interest method is not material to the consolidated financial statements. Debt issuance costs of $235 and $207, as of September 30, 2020 and 2019, respectively, were netted with long-term debt less current portion on the consolidated balance sheets. Upon prepayment of the related debt, the Company accelerates the recognition of an appropriate amount of the costs as refinancing or extinguishment of debt. |
New Accounting Pronouncements | (o) New Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued updated guidance on leases which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. On October 1, 2019, the Company adopted ASC 842 Leases (ASU 2016-02) and all the related amendments to its lease contracts using the modified retrospective method. The effective date was used as the Company’s date of initial application with no restatement of prior periods. As such prior periods continue to be reported under the accounting standards in effect for those periods. The Company recorded upon adoption a financing right-of-use asset and lease liability on the consolidated balance sheet of $4,628 and $4,650, respectively, and an operating right-of-use asset and lease liability of $4,581 and $4,687, respectively. The lease liability reflects the present value of the Company’s estimated future minimum lease payments over the term of the lease, which includes options that are reasonably certain to be exercised, discounted utilizing a collateralized incremental borrowing rate. The impact of the new lease standard does not affect the Company’s operating cash flows. See Note 6 for additional information. In June 2016, the FASB issued ASU 2016-13 “Financial Instruments (Topic 326) Measurement of Credit Losses on Financial Instrument” “CECL”). ASU 2016-13 requires an allowance for expected credit losses on financial assets to be recognized as early as day one of the instrument. This ASU departs from the incurred loss model which means the probability threshold is removed. It considers more forward-looking information and requires the entity to estimate its credit losses as far as it can reasonably estimate. This update became effective for the Company on October 1, 2020. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. |
Building Lease | (p) Building Lease The Lease Agreement with Cook Biotech, Inc. (“lessee”) for a portion of the Company’s headquarters facility is recorded as an operating lease with the escalating rents being recognized on a straight-line basis once the lessee took full possession of the space on May 1, 2015 through the end of the lease on December 31, 2024. The straight-line rents of $53 per month are recorded as a reduction to general and administrative expenses on the consolidated statements of operations and other accounts receivable on the consolidated balance sheets. The cash rent received is recorded in lease rent receivable on the consolidated balance sheets. The variance between the straight-line rents recognized and the actual cash rents received will net to zero by the end of the agreement on December 31, 2024 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Summary of changes in the Company's contract liabilities | Fiscal year ended September 30, 2020 2019 Opening balance $ 6,726 $ 4,925 Additions 106,956 34,650 Deductions (102,290) (32,849) Ending balance $ 11,392 $ 6,726 |
Schedule Of Valuation And Qualifying Accounts Disclosure | A summary of activity in our allowance for doubtful accounts is as follows: Fiscal year ended September 30, 2020 2019 Opening balance $ 1,759 $ 1,948 Charged to expense 180 — Uncollectible invoices written off (1,378) (49) Amounts collected — (140) Ending balance $ 561 $ 1,759 |
Schedule Of Movement In Inventory Reserve | A summary of activity in our inventory obsolescence is as follows for the years ended September 30, 2020 and 2019: Fiscal year ended September 30, 2020 2019 Opening balance $ 198 $ 188 Provision for slow moving and obsolescence 84 97 Write-off of obsolete and slow moving inventory (105) (87) Closing balance $ 177 $ 198 |
Schedule of Property, Plant and Equipment | Property and equipment, net, as of September 30, 2020 and 2019 consisted of the following: 2020 2019 Land and improvements $ 1,755 $ 1,048 Buildings and improvements 29,882 22,418 Machinery and equipment 30,731 25,323 Office furniture and fixtures 950 905 Construction in progress 718 6,010 64,036 55,704 Less: accumulated depreciation (35,307) (32,876) Net property and equipment $ 28,729 $ 22,828 |
Schedule of Changes in the balances of the intangible assets | The changes in the balances of the intangible assets for the years ended September 30, 2020 and 2019 are as follows: Client Non-Compete Trademarks Relationships Agreements Backlog Patents Totals Balance as of October 1, 2018 $ 1,150 $ 1,918 $ 178 $ 72 $ 16 $ 3,334 Amortization (78) (248) (47) (72) (6) (451) Balance as of September 30, 2019 $ 1,072 $ 1,670 $ 131 $ — $ 10 $ 2,883 Acquisition of PCRS 460 1,280 220 121 — 2,081 Amortization (103) (380) (93) (121) (6) (703) Balance as of September 30, 2020 $ 1,429 $ 2,570 $ 258 $ — $ 4 $ 4,261 |
Schedule of Future amortization expense | Future amortization expense for intangible assets at September 30, 2020 for the next five years and a total, thereafter, are as follows: 2021 2022 2023 2024 2025 Thereafter Totals Trademarks 109 109 109 109 109 884 1,429 Client Relationships 408 408 408 408 408 530 2,570 Non-Compete Agreements 102 91 55 10 - - 258 Patents 4 - - - - - 4 $ 623 $ 608 $ 572 $ 527 $ 517 $ 1,414 $ 4,261 |
LOSS PER SHARE (Tables)
LOSS PER SHARE (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
LOSS PER SHARE | |
Schedule of computation of basic net loss per share | Computation of basic net loss per share is shown in the following table: Years Ended September 30, 2020 2019 Basic net (loss) per share: Net loss applicable to common shareholders $ (4,685) $ (790) Weighted average common shares outstanding 10,851 10,383 Basic net loss per share $ (0.43) $ (0.08) |
INVENTORIES (Tables)
INVENTORIES (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
INVENTORIES | |
Schedule of inventories | Inventories consisted of the following: As of September 30, 2020 2019 Raw materials $ 577 $ 858 Work in progress 70 89 Finished goods 230 346 $ 877 $ 1,293 Obsolescence reserve (177) (198) $ 700 $ 1,095 |
LEASES (Tables)
LEASES (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
LEASES | |
Summary of right-of-use lease assets and lease liabilities that are reported in the Company's condensed consolidated balance sheets | As of September 30, 2020 Operating right-of-use assets, net $ 4,001 Current portion of operating lease liabilities 866 Long-term operating lease liabilities 3,344 Total operating lease liabilities $ 4,210 Finance right-of-use assets, net $ 4,778 Current portion of finance lease liabilities 4,728 Long-term finance lease liabilities 44 Total finance lease liabilities $ 4,772 |
Summary of components of lease expense | Twelve months ended September 30, 2020 Operating lease costs: Fixed operating lease costs $ 906 Short-term lease costs 41 Variable lease costs 1 Sublease income (636) Finance lease costs: Amortization of right-of-use asset expense 145 Interest on finance lease liability 283 Total lease cost $ 740 |
Summary of supplemental cash flow information related to leases | Twelve months Ended September 30, 2020 Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 948 Operating cash flows from finance leases 283 Finance cash flows from finance leases 145 Non-cash lease activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 448 |
Summary of weighted average remaining lease term and discount rate | As of September 30, 2020 Weighted-average remaining lease term (in years) Operating lease Finance lease 0.88 Weighted-average discount rate (in percentages) Operating lease 5.23 % Finance lease 5.87 % |
Summary of maturities of operating lease liabilities for each of the following five years and a total thereafter | Operating Leases Finance Leases 2021 $ 896 $ 4,929 2022 938 19 2023 979 13 2024 1,349 13 2025 452 5 Thereafter 194 — Total minimum future lease payments 4,808 4,979 Less interest (598) (207) Total lease liability 4,210 4,772 |
Summary of maturities of finance lease liabilities for each of the following five years and a total thereafter | Operating Leases Finance Leases 2021 $ 896 $ 4,929 2022 938 19 2023 979 13 2024 1,349 13 2025 452 5 Thereafter 194 — Total minimum future lease payments 4,808 4,979 Less interest (598) (207) Total lease liability 4,210 4,772 |
DEBT (Tables)
DEBT (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
DEBT | |
Schedule of Long-term debt | Long-term debt is detailed in the table below. As of: September 30, 2020 September 30, 2019 Initial term loan $ 3,748 $ 3,990 Second term loan 4,004 4,715 Third term loan 1,115 1,271 Fourth term loan 1,425 — Fifth term loan 1,891 — Initial Capex line 920 — Subtotal term loans 13,103 9,976 Construction and equipment loans 5,496 4,301 Seller note – Smithers Avanza 650 810 Seller note – Pre-Clinical Research Services 752 — Paycheck protection program loan 5,051 — 25,052 15,087 Less: Current portion (5,991) (1,109) Less: Debt issue costs not amortized (235) (207) Total Long-term debt $ 18,826 $ 13,771 |
Schedule of Maturities of Long-term Debt | The following table summarizes the combined aggregate amount of maturities over the next five fiscal years: 2021 2022 2023 2024 2025 Thereafter Total Long-term debt $ 5,991 $ 8,110 $ 4,075 $ 1,608 $ 5,227 $ 41 $ 25,052 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
INCOME TAXES | |
Schedule of Deferred Tax Assets and Liabilities | Significant components of our deferred tax assets and liabilities are as follows: As of September 30, 2020 2019 Deferred tax assets: Inventory $ 85 $ 102 Accrued compensation and vacation 137 162 Accrued expenses and other 172 379 Domestic net operating loss carryforwards 3,580 3,282 Basis difference for intangible assets 457 254 Stock compensation expense 96 2 AMT credit carryover — 31 Leases 108 — PPP loan expenses 1,276 — Total deferred tax assets 5,911 4,212 Deferred tax liabilities: Prepaid expenses (143) (121) Basis difference for fixed assets (211) (219) Goodwill (141) — Total deferred tax liabilities (495) (340) Total net deferred tax assets 5,416 3,872 Valuation allowance for net deferred tax assets (5,557) (3,841) Net deferred tax asset (liability) $ (141) $ 31 |
Schedule of Components of Income Tax Expense (Benefit) | Significant components of the provision (benefit) for income taxes are as follows as of the year ended September 30: 2020 2019 Current: Federal $ (31) $ (31) State and local 6 4 Deferred: Federal 143 31 State and local 29 — Income tax expense $ 147 $ 4 |
Schedule of Effective Income Tax Rate Reconciliation | The effective income tax rate on continuing operations varied from the statutory federal income tax rate as follows: 2020 2019 Federal statutory income tax rate 21.0 % 21.0 % Increases (decreases): State and local income taxes, net of Federal tax benefit, if applicable (0.1) % (0.4) % Other nondeductible expenses 1.3 % (11.5) % Goodwill (3.1) % — Valuation allowance changes (22.3) % (9.6) % Effective income tax rate (3.2) % (0.5) % |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
STOCK-BASED COMPENSATION | |
Schedule of weighted-average assumptions used to compute the fair value of the options granted | The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30, 2020 and 2019 were as follows: 2020 2019 Risk-free interest rate 1.36 % 2.47 % Dividend yield 0.00 % 0.00 % Volatility of the expected market price of the Company’s common shares 76.56 % 72.14 % Expected life of the options (years) 5.95 5.95 |
Schedule of stock option activity | A summary of our stock option activity for all options and related information for the year ended September 30, 2020, is as follows (in thousands except for share prices): Weighted- Weighted- Average Average Remaining Aggregate Options Exercise Contractual Intrinsic (shares) Price Life Value Outstanding - October 1, 2019 776 $ 1.61 7.98 $ 1,536 Exercised (154) $ 1.56 Granted 152 $ 4.56 Forfeited (62) $ 2.05 Outstanding - September 30, 2020 712 $ 2.21 7.59 $ 1,939 Exercisable at September 30, 2020 281 $ 1.64 6.38 $ 922 |
Schedule of restricted share activity | Weighted- Average Grant Restricted Shares Date Fair Value Outstanding - September 30, 2019 20 $ 2.0 Granted 126 $ 4.2 Unvested shares forfeited (18) $ 4.0 Outstanding - September 30, 2020 128 $ 3.9 |
BUSINESS COMBINATIONS (Tables)
BUSINESS COMBINATIONS (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
BUSINESS COMBINATIONS | |
Schedule of Unaudited pro forma information | Twelve Months Ended September 30, 2019 Total revenues $ 51,661 Net loss (2,808) Pro forma basic net loss per share $ (0.26) Pro forma diluted net loss per share $ (0.26) |
Smithers Avanza Toxicology Services LLC acquisition | |
BUSINESS COMBINATIONS | |
Schedule of Preliminary purchase price allocation | Allocation as of September 30, 2020 Assets acquired and liabilities assumed: Receivables $ 1,128 Property and equipment 1,564 Prepaid expenses 147 Goodwill 545 Accrued expenses (219) Customer advances (570) $ 2,595 |
PCRS acquisition | |
BUSINESS COMBINATIONS | |
Schedule of Preliminary purchase price allocation | Allocation as of September 30, 2020 Assets acquired and liabilities assumed: Receivable $ 578 Property and equipment 2,836 Unbilled receivables 162 Prepaid expenses 27 Intangible assets 2,081 Goodwill 751 Accounts payable (109) Accrued expenses (118) Customer advances (351) $ 5,857 |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 12 Months Ended |
Sep. 30, 2020 | |
SEGMENT INFORMATION | |
Schedule of operating segments | (a) Operating Segments Years Ended September 30, 2020 2019 Revenue: Services $ 57,177 $ 39,048 Products 3,292 4,568 $ 60,469 $ 43,616 Operating income (loss): Services $ 8,210 $ 5,579 Products (437) (95) Unallocated corporate (10,836) (5,636) $ (3,063) $ (153) Interest expense (1,490) (642) Other income 15 9 Income (loss) before income taxes $ (4,538) $ (786) Years Ended September 30, Years Ended September 30, 2020 2019 2020 2019 Identifiable assets: Depreciation and amortization: Services $ 54,480 $ 35,695 Services $ 3,127 $ 2,017 Products 1,535 1,780 Products 23 19 Unallocated corporate 5,578 4,505 Unallocated corporate 779 681 $ 61,593 $ 41,980 $ 3,929 $ 2,717 Goodwill, net: Capital expenditures: Services $ 4,368 $ 3,617 Services $ 4,781 $ 5,936 Products — — Products 9 29 Unallocated corporate — — Unallocated corporate 1,410 913 $ 4,368 $ 3,617 $ 6,200 $ 6,878 |
Schedule of Geographical Information | (b) Geographic Information Years Ended September 30, 2020 2019 Sales to External Customers: United States $ 56,253 $ 39,634 Other North America 148 218 Pacific Rim 2,826 2,407 Europe 1,207 1,217 Other 35 140 $ 60,469 $ 43,616 Long-lived Assets: United States $ 28,729 $ 22,828 $ 28,729 $ 22,828 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Changes in the Company's contract liabilities | ||
Opening balance | $ 6,726 | $ 4,925 |
Additions | 106,956 | 34,650 |
Deductions | (102,290) | (32,849) |
Ending balance | $ 11,392 | $ 6,726 |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Opening balance | $ 1,759 | $ 1,948 |
Charged to expense | 180 | 0 |
Uncollectible invoices written off | (1,378) | (49) |
Amounts collected | 0 | (140) |
Ending balance | $ 561 | $ 1,759 |
SUMMARY OF SIGNIFICANT ACCOUN_6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Opening balance | $ 198 | $ 188 |
Provision for slow moving and obsolescence | 84 | 97 |
Write-off of obsolete and slow moving inventory | (105) | (87) |
Closing balance | $ 177 | $ 198 |
SUMMARY OF SIGNIFICANT ACCOUN_7
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Land and improvements | $ 1,755 | $ 1,048 |
Buildings and improvements | 29,882 | 22,418 |
Machinery and equipment | 30,731 | 25,323 |
Office furniture and fixtures | 950 | 905 |
Construction in progress | 718 | 6,010 |
Property, Plant and Equipment, Gross, Total | 64,036 | 55,704 |
Less: accumulated depreciation | (35,307) | (32,876) |
Net property and equipment | $ 28,729 | $ 22,828 |
SUMMARY OF SIGNIFICANT ACCOUN_8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Changes in the balances of intangible assets (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Finite-lived Intangible Assets [Roll Forward] | ||
Amortization of intangible assets beginning balance | $ 2,883 | $ 3,334 |
Acquisition of PCRS | 2,081 | |
Amortization | (703) | (451) |
Amortization of intangible assets ending balance | 4,261 | 2,883 |
Trademarks [Member] | ||
Finite-lived Intangible Assets [Roll Forward] | ||
Amortization of intangible assets beginning balance | 1,072 | 1,150 |
Acquisition of PCRS | 460 | |
Amortization | (103) | (78) |
Amortization of intangible assets ending balance | 1,429 | 1,072 |
Client Relationships [Member] | ||
Finite-lived Intangible Assets [Roll Forward] | ||
Amortization of intangible assets beginning balance | 1,670 | 1,918 |
Acquisition of PCRS | 1,280 | |
Amortization | (380) | (248) |
Amortization of intangible assets ending balance | 2,570 | 1,670 |
Noncompete Agreements [Member] | ||
Finite-lived Intangible Assets [Roll Forward] | ||
Amortization of intangible assets beginning balance | 131 | 178 |
Acquisition of PCRS | 220 | |
Amortization | (93) | (47) |
Amortization of intangible assets ending balance | 258 | 131 |
Backlog [Member] | ||
Finite-lived Intangible Assets [Roll Forward] | ||
Amortization of intangible assets beginning balance | 72 | |
Acquisition of PCRS | 121 | |
Amortization | (121) | (72) |
Patents [Member] | ||
Finite-lived Intangible Assets [Roll Forward] | ||
Amortization of intangible assets beginning balance | 10 | 16 |
Acquisition of PCRS | 0 | |
Amortization | (6) | (6) |
Amortization of intangible assets ending balance | $ 4 | $ 10 |
SUMMARY OF SIGNIFICANT ACCOUN_9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Future amortization expense (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2018 |
Finite-Lived Intangible Assets | |||
2021 | $ 623 | ||
2022 | 608 | ||
2023 | 572 | ||
2024 | 527 | ||
2025 | 517 | ||
Thereafter | 1,414 | ||
Totals | 4,261 | $ 2,883 | $ 3,334 |
Trademarks [Member] | |||
Finite-Lived Intangible Assets | |||
2021 | 109 | ||
2022 | 109 | ||
2023 | 109 | ||
2024 | 109 | ||
2025 | 109 | ||
Thereafter | 884 | ||
Totals | 1,429 | 1,072 | 1,150 |
Client Relationships [Member] | |||
Finite-Lived Intangible Assets | |||
2021 | 408 | ||
2022 | 408 | ||
2023 | 408 | ||
2024 | 408 | ||
2025 | 408 | ||
Thereafter | 530 | ||
Totals | 2,570 | 1,670 | 1,918 |
Noncompete Agreements [Member] | |||
Finite-Lived Intangible Assets | |||
2021 | 102 | ||
2022 | 91 | ||
2023 | 55 | ||
2024 | 10 | ||
2025 | 0 | ||
Thereafter | 0 | ||
Totals | 258 | 131 | 178 |
Patents [Member] | |||
Finite-Lived Intangible Assets | |||
2021 | 4 | ||
2022 | 0 | ||
2023 | 0 | ||
2024 | 0 | ||
2025 | 0 | ||
Thereafter | 0 | ||
Totals | $ 4 | $ 10 | $ 16 |
SUMMARY OF SIGNIFICANT ACCOU_10
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional information (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Sep. 30, 2020 | Sep. 30, 2019 | Oct. 01, 2019 | Sep. 30, 2018 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Total revenue recognized | $ 60,469 | $ 43,616 | ||
Allowance for Doubtful Accounts Receivable, Current | 561 | 1,759 | ||
Depreciation | 3,126 | 2,223 | ||
Goodwill | 4,368 | 3,617 | ||
Total amount of intangible assets subject to amortization | 4,261 | 2,883 | $ 3,334 | |
Amortization of Intangible Assets | 703 | 451 | ||
Research and Development Expense | 950 | 627 | ||
Debt Issuance Costs, Noncurrent, Net | 235 | 207 | ||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net | 751 | |||
Finance right-of-use assets | 4,778 | 0 | ||
Finance lease liability | 4,772 | |||
Operating right-of -use asset | 4,001 | 0 | ||
Operating lease liability | 4,210 | |||
Straight-line rent per month | 53 | |||
Variance between the straight-line rents recognized and the actual cash rents received | $ 0 | |||
Restatement | Accounting Standards Update 2016-02 [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Finance right-of-use assets | $ 4,628 | |||
Finance lease liability | 4,650 | |||
Operating right-of -use asset | 4,581 | |||
Operating lease liability | $ 4,687 | |||
Building and Building Improvements [Member] | Minimum | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Property, Plant and Equipment, Useful Life | 34 years | |||
Building and Building Improvements [Member] | Maximum | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Property, Plant and Equipment, Useful Life | 40 years | |||
Machinery and Equipment [Member] | Minimum | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Property, Plant and Equipment, Useful Life | 5 years | |||
Machinery and Equipment [Member] | Maximum | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Property, Plant and Equipment, Useful Life | 10 years | |||
Furniture and Fixtures [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Property, Plant and Equipment, Useful Life | 10 years | |||
Royalty revenue [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Total revenue recognized | $ 641 | $ 349 |
SALE OF PREFERRED SHARES AND _2
SALE OF PREFERRED SHARES AND WARRANTS (Details) - $ / shares | May 11, 2011 | Sep. 30, 2020 | Sep. 30, 2019 |
SALE OF PREFERRED SHARES AND WARRANTS | |||
Units Issued During Period Shares New Issues | 5,506 | ||
Shares Issued, Price Per Share | $ 1,000 | ||
Series A Preferred Stock [Member] | |||
SALE OF PREFERRED SHARES AND WARRANTS | |||
Preferred Stock, Dividend Rate, Percentage | 6.00% | ||
Convertible Preferred Stock, Shares Issued upon Conversion | 500 | ||
Convertible Preferred Stock Aggregate Shares Issued Upon Conversion | 2,753,000 | ||
Share Price | $ 1.86 | ||
Conversion of Stock, Shares Converted | 5,481 | ||
Conversion of Stock, Shares Issued | 3,144,108 | ||
Common Stock Dividends, Shares | 217,366 | ||
Preferred Stock, Shares Outstanding | 25 | 35 |
LOSS PER SHARE - Additional Inf
LOSS PER SHARE - Additional Information (Details) - shares shares in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Convertible Preferred Stock [Member] | ||
LOSS PER SHARE | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 17 | 12 |
Employee Stock Option [Member] | ||
LOSS PER SHARE | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 776 | 712 |
LOSS PER SHARE - Basic net loss
LOSS PER SHARE - Basic net loss per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Basic net loss per share: | ||
Net loss applicable to common shareholders | $ (4,685) | $ (790) |
Weighted average common shares outstanding | 10,851 | 10,383 |
Basic net loss per share | $ (0.43) | $ (0.08) |
Diluted net loss per share: | ||
Diluted weighted average common shares outstanding | 10,851 | 10,383 |
Diluted net loss per share | $ (0.43) | $ (0.08) |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
INVENTORIES | ||
Raw materials | $ 577 | $ 858 |
Work in progress | 70 | 89 |
Finished goods | 230 | 346 |
Gross inventories | 877 | 1,293 |
Obsolescence reserve | (177) | (198) |
Inventories | $ 700 | $ 1,095 |
LEASES (Details)
LEASES (Details) | 12 Months Ended |
Sep. 30, 2020 | |
Lessee, Lease, Description [Line Items] | |
Renewal option, operating lease | true |
Renewal option, finance lease | true |
Lease, Practical Expedients, Package [true false] | true |
Lease, Practical Expedient, Lessor Single Lease Component [true false] | true |
Lease, Practical Expedient, Land Easement [true false] | true |
Facilities leases | Minimum | |
Lessee, Lease, Description [Line Items] | |
Lease term, operating lease | 2 years |
Lease term, finance lease | 2 years |
Facilities leases | Maximum | |
Lessee, Lease, Description [Line Items] | |
Lease term, operating lease | 10 years |
Lease term, finance lease | 10 years |
Equipment leases | Minimum | |
Lessee, Lease, Description [Line Items] | |
Lease term, operating lease | 30 months |
Lease term, finance lease | 30 months |
Equipment leases | Maximum | |
Lessee, Lease, Description [Line Items] | |
Lease term, operating lease | 60 months |
Lease term, finance lease | 60 months |
LEASES - Right-of-use lease ass
LEASES - Right-of-use lease assets and lease liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
Right-of-use lease assets and lease liabilities | ||
Operating lease right-of use-assets, net | $ 4,001 | $ 0 |
Current portion of operating lease liabilities | 866 | 0 |
Long-term operating lease liabilities | 3,344 | 0 |
Total operating lease liabilities | 4,210 | |
Finance lease right-to use assets, net | 4,778 | 0 |
Current portion of finance lease liabilities | 4,728 | 0 |
Long-term finance lease liabilities | 44 | $ 0 |
Total finance lease liabilities | $ 4,772 |
LEASES - Operating lease (Detai
LEASES - Operating lease (Details) $ in Thousands | 12 Months Ended |
Sep. 30, 2020USD ($) | |
LEASES | |
Amortization of operating lease | $ 906 |
Amortization of right-of-use asset expense | 145 |
Finance lease interest | 283 |
Variable payments for lease | $ 126 |
LEASES - Components of lease ex
LEASES - Components of lease expense (Details) $ in Thousands | 12 Months Ended |
Sep. 30, 2020USD ($) | |
Operating lease costs: | |
Fixed operating lease costs | $ 906 |
Short-term lease costs | 41 |
Variable lease costs | 1 |
Sublease income | (636) |
Finance lease costs: | |
Amortization of right-of-use asset expense | 145 |
Interest on finance lease liability | 283 |
Total lease cost | $ 740 |
LEASES - Weighted average remai
LEASES - Weighted average remaining lease (Details) $ in Thousands | 12 Months Ended |
Sep. 30, 2020USD ($) | |
Cash flows included in the measurement of lease liabilities: | |
Operating cash flows from operating leases | $ 948 |
Operating cash flows from finance leases | 283 |
Finance cash flows from finance leases | 145 |
Non-cash lease activity: | |
Right-of-use assets obtained in exchange for new operating lease liabilities | $ 448 |
Operating lease, weighted-average remaining lease term (in years) | 4 years 9 months 22 days |
Finance lease, weighted-average remaining lease term (in years) | 10 months 17 days |
Operating lease, weighted-average discount rate (in percentages) | 5.23% |
Finance lease, weighted-average discount rate (in percentages) | 5.87% |
LEASES - Maturities of operatin
LEASES - Maturities of operating and finance lease (Details) $ in Thousands | Sep. 30, 2020USD ($) |
Maturities of operating lease liabilities | |
2021 | $ 896 |
2022 | 938 |
2023 | 979 |
2024 | 1,349 |
2025 | 452 |
Thereafter | 194 |
Total minimum future lease payments | 4,808 |
Less interest | (598) |
Total operating lease liabilities | 4,210 |
2021 | 4,929 |
2022 | 19 |
2023 | 13 |
2024 | 13 |
2025 | 5 |
Total minimum future lease payments | 4,979 |
Less interest | (207) |
Total finance lease liabilities | $ 4,772 |
DEBT (Details)
DEBT (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
DEBT ARRANGEMENTS | ||
Long-term Debt | $ 25,052 | $ 15,087 |
Less: Current portion | (5,991) | (1,109) |
Less: Debt issue costs not amortized | (235) | (207) |
Total Long-term debt | 18,826 | 13,771 |
Construction and Equipment Loans [Member] | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 5,496 | 4,301 |
Term Loan [Member] | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 13,103 | 9,976 |
Initial Term Loan [Member] | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 3,748 | 3,990 |
Second Term Loan | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 4,004 | 4,715 |
Third Term Loan | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 1,115 | 1,271 |
Fourth Term Loan | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 1,425 | 0 |
Fifth Term loan | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 1,891 | 0 |
Initial Capex Line | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 920 | 0 |
Seller Note [Member] | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 752 | 0 |
Smithers Avanza Toxicology Services LLC acquisition | Unsecured promissory note | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | 650 | 810 |
PCRS acquisition | Unsecured promissory note | ||
DEBT ARRANGEMENTS | ||
Long-term Debt | $ 5,051 | $ 0 |
DEBT - Additional Information (
DEBT - Additional Information (Details) $ in Thousands | Nov. 16, 2020USD ($)item | Aug. 01, 2020USD ($) | Apr. 23, 2020USD ($) | Mar. 27, 2020USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Dec. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 |
DEBT ARRANGEMENTS | |||||||||
Interest Paid, Including Capitalized Interest, Operating and Investing Activities | $ 1,039 | $ 566 | |||||||
Long-term Debt | 25,052 | 15,087 | |||||||
Minimum | President and Chief Executive Officer [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Life Insurance, Corporate or Bank Owned, Amount | $ 5,000 | ||||||||
Credit Arrangements [Member] | Maximum | |||||||||
DEBT ARRANGEMENTS | |||||||||
Minimum Debt Service Coverage Ratio One | 1.25 | ||||||||
Cash Flow Leverage Ratio | 4.25 | 4 | 4.50 | 5 | |||||
Credit Arrangements [Member] | Minimum | |||||||||
DEBT ARRANGEMENTS | |||||||||
Minimum Debt Service Coverage Ratio One | 1 | ||||||||
Cash Flow Leverage Ratio | 1 | 1 | 1 | 1 | |||||
First Internet Bank of Indiana [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Periodic Payment | $ 33 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 3.99% | ||||||||
Debt Instrument, Face Amount | $ 4,500 | ||||||||
Long-term Debt, Gross | 3,748 | ||||||||
First Internet Bank of Indiana [Member] | Equipment Draw Loan [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Long-term Debt | 1,266 | ||||||||
Line of Credit Facility, Additional Borrowing Capacity | 1,429 | ||||||||
First Internet Bank of Indiana [Member] | Construction Draw Loan [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Long-term Debt | 4,230 | ||||||||
Line of Credit Facility, Additional Borrowing Capacity | 4,445 | ||||||||
First Internet Bank of Indiana [Member] | Revolving Credit Facility [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Line of Credit Facility, Additional Borrowing Capacity | $ 5,000 | ||||||||
Basis points deducted from prime rate | 0.00% | ||||||||
Smithers Avanza Toxicology Services LLC acquisition | Unsecured promissory note | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | ||||||||
Debt Instrument, Face Amount | $ 810 | ||||||||
Long-term Debt | $ 650 | ||||||||
PCRS acquisition | Unsecured promissory note | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.50% | ||||||||
Debt Instrument, Face Amount | $ 800 | ||||||||
Long-term Debt | 752 | ||||||||
Initial Term Loan [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Long-term Debt | 3,748 | 3,990 | |||||||
Subsequent Term Loan [Member] | First Internet Bank of Indiana [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Periodic Payment | $ 78 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.06% | ||||||||
Debt Instrument, Face Amount | $ 5,500 | ||||||||
Long-term Debt | 4,004 | ||||||||
Third Term Loan | |||||||||
DEBT ARRANGEMENTS | |||||||||
Long-term Debt | 1,115 | 1,271 | |||||||
Third Term Loan | First Internet Bank of Indiana [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Periodic Payment | $ 20 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.63% | ||||||||
Debt Instrument, Face Amount | $ 1,271 | ||||||||
Long-term Debt | 1,115 | ||||||||
Fifth Term loan | |||||||||
DEBT ARRANGEMENTS | |||||||||
Long-term Debt | $ 1,891 | 0 | |||||||
Fifth Term loan | First Internet Bank of Indiana [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.00% | ||||||||
Debt Instrument, Face Amount | $ 1,939 | ||||||||
Long-term Debt | 1,891 | ||||||||
Fourth Term Loan | |||||||||
DEBT ARRANGEMENTS | |||||||||
Long-term Debt | $ 1,425 | $ 0 | |||||||
Fourth Term Loan | First Internet Bank of Indiana [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.00% | ||||||||
Debt Instrument, Face Amount | $ 1,500 | ||||||||
Long-term Debt | $ 1,425 | ||||||||
Current Credit Agreement [Member] | First Internet Bank of Indiana [Member] | Construction Draw Loan [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.20% | ||||||||
Capex Line [Member] | First Internet Bank of Indiana [Member] | Capital Expenditure Line of Credit [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Periodic Payment | $ 17 | ||||||||
Debt Instrument, Face Amount | $ 948 | $ 1,100 | |||||||
Long-term Debt | $ 920 | ||||||||
Basis points deducted from prime rate | 4.00% | ||||||||
Second Capex Line [Member] | First Internet Bank of Indiana [Member] | Revolving Credit Facility [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Long-term Debt | $ 2,613 | ||||||||
Second Capex Line [Member] | First Internet Bank of Indiana [Member] | Capital Expenditure Line of Credit [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Face Amount | $ 3,000 | ||||||||
Basis points deducted from prime rate | 0.50% | ||||||||
Second Capex Line [Member] | First Internet Bank of Indiana [Member] | Capital Expenditure Line of Credit [Member] | Base Rate [Member] | |||||||||
DEBT ARRANGEMENTS | |||||||||
Basis points deducted from prime rate | 4.00% | ||||||||
Payroll Protection Payroll (PPP) Program Loan | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Face Amount | $ 5,051 | ||||||||
Forgiveness of the loan | $ 4,851 | ||||||||
Payroll Protection Payroll (PPP) Program Loan | Huntington National Bank | |||||||||
DEBT ARRANGEMENTS | |||||||||
Debt Instrument, Periodic Payment | $ 283 | ||||||||
Debt Instrument, Face Amount | $ 5,051 | ||||||||
Number of installments for repayment | item | 18 | ||||||||
Forgiveness of the loan | $ 4,851 |
DEBT - Annual principal payment
DEBT - Annual principal payments (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
DEBT | ||
2021 | $ 5,991 | |
2022 | 8,110 | |
2023 | 4,075 | |
2024 | 1,608 | |
2025 | 5,227 | |
Thereafter | 41 | |
Long-term Debt | $ 25,052 | $ 15,087 |
INCOME TAXES - Deferred tax ass
INCOME TAXES - Deferred tax assets and liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
Deferred tax assets: | ||
Inventory | $ 85 | $ 102 |
Accrued compensation and vacation | 137 | 162 |
Accrued expenses and other | 172 | 379 |
Domestic net operating loss carryforwards | 3,580 | 3,282 |
Basic difference for intangible assets | 457 | 254 |
Stock compensation expense | 96 | 2 |
AMT credit carryover | 0 | 31 |
Leases | 108 | 0 |
PPP loan expenses | 1,276 | 0 |
Total deferred tax assets | 5,911 | 4,212 |
Deferred tax liabilities: | ||
Prepaid expenses | (143) | (121) |
Basis difference for fixed assets | (211) | (219) |
Goodwill | (141) | 0 |
Total deferred tax liabilities | (495) | (340) |
Total net deferred tax assets | 5,416 | 3,872 |
Valuation allowance for net deferred tax assets | (5,557) | (3,841) |
Net deferred tax asset (liability) | $ (141) | |
Net deferred tax asset (liability) | $ 31 |
INCOME TAXES - Provision (benef
INCOME TAXES - Provision (benefit) for income taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Current: | ||
Federal | $ (31) | $ (31) |
State and local | 6 | 4 |
Deferred: | ||
Federal | 143 | 31 |
State and local | 29 | 0 |
Income tax expense | $ 147 | $ 4 |
INCOME TAXES - Effective income
INCOME TAXES - Effective income tax rate (Details) | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
INCOME TAXES | ||
Federal statutory income tax rate | 21.00% | 21.00% |
Increases (decreases): | ||
State and local income taxes, net of Federal tax benefit, if applicable | (0.10%) | (0.40%) |
Other nondeductible expenses | 1.30% | (11.50%) |
Goodwill | (3.10%) | 0.00% |
Valuation allowance changes | (22.30%) | (9.60%) |
Effective income tax rate | (3.20%) | (0.50%) |
INCOME TAXES - Additional infor
INCOME TAXES - Additional information (Details) - USD ($) | Mar. 27, 2020 | Sep. 30, 2020 | Sep. 30, 2019 |
INCOME TAXES | |||
Income Taxes Paid | $ 7,000 | $ 7,000 | |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | 21.00% | |
Effective Income Tax Rate Reconciliation, Percent | (3.20%) | (0.50%) | |
Intangible assets amortized for tax purpose as they are tax deductible | 15 years | ||
Additional gross uncertain tax positions | $ 0 | ||
Deferred tax asset, nondeductible expense, PPP loan expenses | $ 1,276,000 | $ 0 | |
Income tax examination year from date of utilization | 3 years | ||
Payroll Protection Payroll (PPP) Program Loan | |||
INCOME TAXES | |||
Proceeds from debt | $ 5,051,000 | ||
Forgiveness | 4,851,000 | ||
Deferred tax asset, nondeductible expense, PPP loan expenses | $ 1,276,000 | ||
Internal Revenue Service (IRS) [Member] | |||
INCOME TAXES | |||
Operating Loss Carryforwards | $ 11,859,000 | ||
Operating Loss Carryforwards, Valuation Allowance | $ 5,557,000 | $ 3,841,000 | |
Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member] | |||
INCOME TAXES | |||
Operating Loss Carryforwards, Expiration Date | Sep. 30, 2032 | ||
Internal Revenue Service (IRS) [Member] | Latest Tax Year [Member] | |||
INCOME TAXES | |||
Operating Loss Carryforwards, Expiration Date | Sep. 30, 2036 | ||
State and Local Jurisdiction [Member] | |||
INCOME TAXES | |||
Loss carryforwards which expires | $ 22,506,000 | ||
Loss carryforwards which may be carried forward indefinitely | $ 465,000 | ||
State and Local Jurisdiction [Member] | Earliest Tax Year [Member] | |||
INCOME TAXES | |||
Operating Loss Carryforwards, Expiration Date | Sep. 30, 2028 | ||
State and Local Jurisdiction [Member] | Latest Tax Year [Member] | |||
INCOME TAXES | |||
Operating Loss Carryforwards, Expiration Date | Sep. 30, 2038 |
STOCK-BASED COMPENSATION - Weig
STOCK-BASED COMPENSATION - Weighted-average fair value (Details) | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
STOCK-BASED COMPENSATION | ||
Risk-free interest rate | 1.36% | 2.47% |
Dividend yield | 0.00% | 0.00% |
Volatility of the expected market price of the Company's common shares | 76.56% | 72.14% |
Expected life of the options (years) | 5 years 11 months 12 days | 5 years 11 months 12 days |
STOCK-BASED COMPENSATION - Stoc
STOCK-BASED COMPENSATION - Stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
STOCK-BASED COMPENSATION | ||
Options (shares) Granted | 152,000 | 503,000 |
Weighted-Average Grant Date Fair Value Granted | $ 3.11 | $ 1.09 |
Employee Stock Option [Member] | ||
STOCK-BASED COMPENSATION | ||
Options (shares) Outstanding | 776 | |
Options (shares) Exercised | (154) | |
Options (shares) Granted | 152 | |
Options (shares) Forfeited | (62) | |
Options (shares) Outstanding | 712 | 776 |
Options (shares) Exercisable | 281 | |
Weighted-Average Exercise Price Outstanding | $ 1.61 | |
Weighted-Average Exercise Price Exercised | 1.56 | |
Weighted-Average Exercise Price Granted | 4.56 | |
Weighted-Average Exercise Price Forfeited | 2.05 | |
Weighted-Average Exercise Price Outstanding | 2.21 | $ 1.61 |
Weighted-Average Exercise Price Exercisable | $ 1.64 | |
Weighted-Average Remaining Contractual Life Exercisable | 6 years 4 months 17 days | 7 years 11 months 23 days |
Aggregate Intrinsic Value Outstanding | $ 1,939 | $ 1,536 |
Aggregate Intrinsic Value Exercisable | $ 922 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 7 years 7 months 2 days |
STOCK BASED COMPENSATION - Rest
STOCK BASED COMPENSATION - Restricted share activity (Details) - Restricted common shares | 12 Months Ended |
Sep. 30, 2020$ / sharesshares | |
Outstanding - September 30, 2019 | shares | 20 |
Granted | shares | 126 |
Forfeited | shares | (18) |
Outstanding - September 30, 2020 | shares | 128 |
Outstanding at the beginning | $ / shares | $ 2 |
Granted (in dollars per share) | $ / shares | 4.2 |
Unvested shares forfeited (in dollars per share) | $ / shares | 4 |
Outstanding at the end | $ / shares | $ 3.9 |
STOCK-BASED COMPENSATION - Addi
STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
STOCK-BASED COMPENSATION | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 814 | |
Fair value of unrestricted shares | $ 528 | |
Stock based compensation expense | 540 | $ 278 |
Total intrinsic value of stock options exercised | $ 562 | $ 19 |
Weighted average estimated fair value of stock options granted | $ 3.11 | $ 1.09 |
Two Thousand Eighteen Equity Incentive Plan [Member] | ||
STOCK-BASED COMPENSATION | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 700 | |
Employee Stock Option [Member] | ||
STOCK-BASED COMPENSATION | ||
Employee Service Share-based Compensation, Non-vested Awards, Compensation Not yet Recognized, Stock Options | $ 545 | |
Employee Service Share-based Compensation, Non-vested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years | |
Stock based compensation expense | $ 540 | |
Restricted common shares | ||
STOCK-BASED COMPENSATION | ||
Employee Service Share-based Compensation, Non-vested Awards, Compensation Not yet Recognized, Stock Options | $ 326 | |
Employee Service Share-based Compensation, Non-vested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 4 months 24 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 126 | |
Stock based compensation expense | $ 278 |
RETIREMENT PLAN (Details)
RETIREMENT PLAN (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
RETIREMENT PLAN | ||
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 50.00% | |
Defined Contribution Plan Employer Contribution Match Maximum Percent Of Employee Contribution | 6.00% | |
Contribution expense | $ 538 | $ 374 |
BUSINESS COMBINATIONS - Prelimi
BUSINESS COMBINATIONS - Preliminary purchase price (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 01, 2019 | May 01, 2019 |
Assets acquired and liabilities assumed: | |||
Intangible assets | $ 2,595 | ||
Total | $ 751 | ||
Smithers Avanza Toxicology Services LLC acquisition | |||
Assets acquired and liabilities assumed: | |||
Receivables | 1,128 | ||
Property and equipment | 1,564 | ||
Prepaid expenses | 147 | ||
Goodwill | 545 | ||
Accrued expenses | (219) | ||
Customer advances | (570) | ||
Total | 2,595 | ||
PCRS acquisition | |||
Assets acquired and liabilities assumed: | |||
Receivables | 578 | ||
Property and equipment | 2,836 | ||
Unbilled receivables | 162 | ||
Prepaid expenses | 27 | ||
Intangible assets | 2,081 | $ 5,857 | |
Goodwill | 751 | ||
Accounts payable | (109) | ||
Accrued expenses | (118) | ||
Customer advances | (351) | ||
Total | $ 5,857 |
BUSINESS COMBINATIONS - Unaudit
BUSINESS COMBINATIONS - Unaudited pro forma (Details) $ / shares in Units, $ in Thousands | 12 Months Ended |
Sep. 30, 2019USD ($)$ / shares | |
BUSINESS COMBINATIONS | |
Total revenues | $ | $ 51,661 |
Net loss | $ | $ (2,808) |
Pro forma basic net loss per share | $ / shares | $ (0.26) |
Pro forma diluted net loss per share | $ / shares | $ (0.26) |
BUSINESS COMBINATIONS - Additio
BUSINESS COMBINATIONS - Additional Information (Details) | Nov. 08, 2019USD ($)shares | May 01, 2019USD ($)itemshares | Sep. 30, 2020USD ($)shares | Sep. 30, 2019USD ($)shares | Dec. 01, 2019USD ($) | Nov. 29, 2019USD ($) |
BUSINESS COMBINATIONS | ||||||
Common Stock, Shares, Issued | shares | 10,977,675 | 10,510,694 | ||||
Payments to Acquire Businesses, Gross | $ 3,931,000 | $ 1,271,000 | ||||
Operating Lease, Payments | 948,000 | |||||
Revenues | 60,469,000 | 43,616,000 | ||||
Net loss | (4,685,000) | $ (790,000) | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill | $ 2,595,000 | |||||
Smithers Avanza Toxicology Services LLC acquisition | ||||||
BUSINESS COMBINATIONS | ||||||
Business Combination, Consideration Transferred | 2,595,000 | |||||
Escrow Deposit Disbursements Related to Property Acquisition | $ 125,000 | |||||
Common Stock, Shares, Issued | shares | 200 | |||||
Payments to Acquire Businesses, Gross | $ 1,271,000 | |||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 394,000 | |||||
Class of Warrant or Right, Covenants Period | 5 years | |||||
Revenues | 10,748,000 | |||||
Net loss | 596,000 | |||||
Smithers Avanza Toxicology Services LLC acquisition | Promissory Note [Member] | ||||||
BUSINESS COMBINATIONS | ||||||
Debt Instrument, Face Amount | $ 810,000 | |||||
Debt Instrument, Interest Rate, Effective Percentage | 6.50% | |||||
PCRS acquisition | ||||||
BUSINESS COMBINATIONS | ||||||
Business Combination, Contingent Consideration, Asset | $ 5,857,000 | |||||
Business Combination, Consideration Transferred | 1,500,000 | |||||
Payments for purchase of certain real property | $ 2,500,000 | |||||
Common Stock, Shares, Issued | shares | 240 | |||||
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $ 1,133,000 | |||||
Business Acquisition, Transaction Costs | 248,000 | |||||
Revenues | 4,780,000 | |||||
Net loss | 176,000 | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill | 2,081,000 | $ 5,857,000 | ||||
PCRS acquisition | Unsecured promissory note | ||||||
BUSINESS COMBINATIONS | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.50% | |||||
Debt Instrument, Face Amount | $ 800,000 | $ 800,000 | ||||
Lease Arrangements [Member] | Smithers Avanza Toxicology Services LLC acquisition | ||||||
BUSINESS COMBINATIONS | ||||||
Lessee, Operating Lease, Term of Contract | 5 years 8 months | |||||
Number of Lease Extension Terms | item | 2 | |||||
Lessee, Operating Lease, Renewal Term | 5 years | |||||
Lease Arrangements [Member] | Smithers Avanza Toxicology Services LLC acquisition | Minimum | ||||||
BUSINESS COMBINATIONS | ||||||
Operating Lease, Payments | $ 400,000 | |||||
Lease Arrangements [Member] | Smithers Avanza Toxicology Services LLC acquisition | Maximum | ||||||
BUSINESS COMBINATIONS | ||||||
Operating Lease, Payments | $ 600,000 |
SEGMENT INFORMATION - Operating
SEGMENT INFORMATION - Operating Segments (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
SEGMENT INFORMATION | ||
Revenue: | $ 60,469 | $ 43,616 |
Operating Income (Loss) | (3,063) | (153) |
Interest expense | (1,490) | (642) |
Other income | 15 | 9 |
Income (loss) before income taxes | (4,538) | (786) |
Identifiable assets: | 61,593 | 41,980 |
Depreciation and amortization: | 3,929 | 2,717 |
Goodwill, net: | 4,368 | 3,617 |
Capital expenditures: | 6,200 | 6,878 |
Services Segment [Member] | ||
SEGMENT INFORMATION | ||
Revenue: | 57,177 | 39,048 |
Operating Income (Loss) | 8,210 | 5,579 |
Identifiable assets: | 54,480 | 35,695 |
Depreciation and amortization: | 3,127 | 2,017 |
Goodwill, net: | 4,368 | 3,617 |
Capital expenditures: | 4,781 | 5,936 |
Products Segment [Member] | ||
SEGMENT INFORMATION | ||
Revenue: | 3,292 | 4,568 |
Operating Income (Loss) | (437) | (95) |
Identifiable assets: | 1,535 | 1,780 |
Depreciation and amortization: | 23 | 19 |
Goodwill, net: | 0 | 0 |
Capital expenditures: | 9 | 29 |
Corporate Segment [Member] | ||
SEGMENT INFORMATION | ||
Identifiable assets: | 5,578 | 4,505 |
Unallocated Corporate Segment [Member] | ||
SEGMENT INFORMATION | ||
Operating Income (Loss) | (10,836) | (5,636) |
Depreciation and amortization: | 779 | 681 |
Capital expenditures: | $ 1,410 | $ 913 |
SEGMENT INFORMATION - Geographi
SEGMENT INFORMATION - Geographic Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
SEGMENT INFORMATION | ||
Revenues | $ 60,469 | $ 43,616 |
Long-Lived Assets | 28,729 | 22,828 |
United States [Member] | ||
SEGMENT INFORMATION | ||
Revenues | 56,253 | 39,634 |
Long-Lived Assets | 28,729 | 22,828 |
Other North America [Member] | ||
SEGMENT INFORMATION | ||
Revenues | 148 | 218 |
Pacific Rim [Member] | ||
SEGMENT INFORMATION | ||
Revenues | 2,826 | 2,407 |
Europe [Member] | ||
SEGMENT INFORMATION | ||
Revenues | 1,207 | 1,217 |
Other [Member] | ||
SEGMENT INFORMATION | ||
Revenues | $ 35 | $ 140 |
ACCRUED EXPENSES (Details)
ACCRUED EXPENSES (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Sep. 30, 2019 |
Restructuring Cost and Reserve [Line Items] | ||
Restructuring Reserve, Current | $ 168 | $ 349 |
Contract Termination [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring reserves | $ 1,117 |
RELATED-PARTY TRANSACTIONS (Det
RELATED-PARTY TRANSACTIONS (Details) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2020USD ($)employeeitem | Sep. 30, 2019USD ($) | Nov. 08, 2019USD ($) | |
RELATED-PARTY TRANSACTIONS | |||
Fees and Reimbursed Travel Costs | $ 76 | $ 75 | |
SWL Properties, LLC [Member] | |||
RELATED-PARTY TRANSACTIONS | |||
Number Of Employees Who Owned Properties | employee | 3 | ||
Number of officers among employees who owned properties | item | 2 | ||
Lease term | 7 years | ||
Number of successive terms for extension of lease term | item | 2 | ||
Threshold period to purchase building | 5 years | ||
Lease expense incurred | $ 390 | 390 | |
LLC Bighorn Holdings [Member] | |||
RELATED-PARTY TRANSACTIONS | |||
Lease term | 5 years | ||
Number of successive terms for extension of lease term | item | 2 | ||
Lease expense incurred | $ 85 | ||
PCRS acquisition | Unsecured promissory note | |||
RELATED-PARTY TRANSACTIONS | |||
Initial principal amount | 800 | $ 800 | |
LS Associates [Member] | |||
RELATED-PARTY TRANSACTIONS | |||
Consulting fees | $ 64 | $ 156 |